Heterocyclic amines having central nervous system activity

ABSTRACT

PCT No. PCT/US90/02621 Sec. 371 Date Dec. 6, 1991 Sec. 102(e) Date Dec. 6, 1991 PCT Filed May 15, 1990.Tricyclic nitrogen containing compounds, having central nervous system activity of the following structural formula:  &lt;IMAGE&gt;  and pharmaceutically acceptable salts thereof wherein R1, R2, and R3 are independently hydrogen, C1-6 alkyl, alkenyl, or alkynyl, C3-10 cycloalkyl, or R1 and R2 are joined to form a C3-7 cyclic amine which can contain additional heteroatoms; X is hydrogen, C1-6 alkyl halogen, hydroxy, alkoxy, cyano, carboxamide, carboxyl, or carboalkoxyl; A is SO2, N, CH, CH2, CHCH3, C=O, C=S, C-SCH3, C=NH, C-NH2, C-NHCH3, C-NHCOOCH3, or C-NHCN. B is CH2, CH, C=O, N, NH or N-CH3; n is 0 or 1; and D is CH, CH2, C=O, O, N, NH or N-CH3. These new compounds are suitable for treating schizophrenia, Parkinson&#39;s disease, anxiety, depression or as compounds for lowering blood pressure in animal or human hosts.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is the national phase of international applicationPCT/US90/02621, filed May 15, 1990, which is the continuation-in-part ofU.S. Ser. No. 07/364,374, filed Jun. 9, 1989, abandoned.

BACKGROUND OF THE INVENTION

The present invention is directed toward tricyclic nitrogen containingcompounds, heterocyclic amines, having central nervous system activity.These new compounds are suitable for treating schizophrenia, Parkinson'sdisease, anxiety or as compounds for lowering blood pressure.

A series of dihydrophenalenes, tricyclic amine substituted compounds,and related compounds having central nervous system activity weredescribed in PCT Int. Pub. No. WO87/04153 and in PCT Int. Pub. No.WO88/04292. A major difference between those compounds and the presentinvention is that the subject compounds have at least one nitrogen atomin the tricyclic ring structure which is shared by two of the ringstructures. Generally, the subject compounds have exhibitedantipsychotic acitivity and better oral bioavailability.

Information Disclosure Statement

PCT Int. Pub. No. WO87/04153 and PCT Int. Pub. No. WO88/04292 eachdescribe tricyclic structures having central nervous system activity.

U.S. Pat. No. 4,110,339 discloses4-(di-n-propyl)amino-1,3,4,5-tetrahydrobenz(cd)indole compounds usefulas prolactin inhibitors and in the treatment of Parkinsonism. EuropeanPatent Application 153,083 and German Patent No. 3,346,573 disclosemethoxy substituted 4-(di-n-propyl)amino-1,3,4,5-tetrahydrobenz(cd)indole compounds. Thesepublications disclose nitrogen containing tricyclic ring structures butthe nitrogen is not shared by any of the rings.

Evans, D. D., Peters, D. J., J. Chem. Soc., Perkin Trans. 1, pp 285-288(1974) discloses nitrogen containing tricyclic ring structures where thenitrogen is shared by two ring structures but additionally includesother substituents not common to the subject compounds.

SUMMARY OF THE INVENTION

In the aspect, the present invention is directed toward tricyclicnitrogen containing compounds of Formula I, having central nervoussystem activity and pharmaceutically acceptable salts. R₁, R₂, and R₃are independently hydrogen, C₁₋₆ alkyl, C₃₋₅ alkenyl, or C₃₋₅ alkynyl,C₃₋₇ cycloalkyl or C₄₋₁₀ cycloalkyl- or phenyl-substituted alkyl, or R₁and R₂ are joined to form a C₃₋₇ cyclic amine which can containadditional heteroatoms and/or unsaturation. X is hydrogen, C₁₋₆ alkyl,halogen, hydroxy, alkoxy, cyano, carboxamide, carboxyl, or carboalkoxyl.A is SO₂, N, CH, CH₂, CHCH₃, C═O, C═S, C--SCH₃, C═NH, C--NH₂, C--NHCH₃,C--NHCOOCH₃, or C--NHCN. B is CH₂, CH, C═O, N, NH or N--CH₃ and n is 0or 1. D is CH₂, C═O, O, N, NH or N--CH₃. These new compounds aresuitable for treating schizophrenia, Parkinson's disease, anxiety,depression, or as compounds for lowering blood pressure.

In another aspect, the invention is a novel compound of the structuralformula XXXV' where W is O or H₂ and R₁ 'and R₂ are independentlyhydrogen or a C₁₋₄ alkyl group. This compound is useful as anintermediate in the preparation of compounds of Formula I. Preferredcompounds are where W is H₂ and R₁ and R₂ are the same such as CH₃ or C₃H₂ groups.

In yet another aspect, the present invention is a method for treatingcentral nervous system (CNS) disorders such as anxiety, depression,hypertension and associated high blood pressure, Parkinson's disease andschizophrenia in animal or human hosts by administering apharmaceutically effective amount of a commond of Formula I includingpharmaceutically acceptable salts. Other uses for these compoundsinclude panic attacks, eating disorders, obsessive-compulsivedisturbances seen in demantia disorders. In addition, central 5-HTreceptor activation are believed to be involved in mediating sexualbehavior. These compounds would be useful to stimulate sexual activityand to alleviate impotence.

DETAILED DESCRIPTION OF THE INVENTION

The present invention describes compounds having central nervous systemactivity. The compounds are identified by a tricyclic ring structurehaving a nitrogen atom shared by two rings to which an amina substituent(NR₁ R₂) is attached as structurally depicted by Formula I on theFormula Sheet, below. Generally, these structures include a variety offused tricyclic organic compounds; structures are shown in the Formulasheets. The systematic names for the ring systems in these compounds maybe found by consulting the Ring Systems Handbook, 1988 edition,published by Chemical Abstracts Service. These names are derived bycombining the names of benzene or a monocyclic heterocycle with the nameof a bicyclic heterocycle to which it is fused. The atoms and bondscommon to the fused rings are then specified to distinguish it fromisomeric systems with similar names.

Included in the invention are the 5-aminoimidazo-(4,5,1-ij)quinolinesand 5-aminoimidazo(4,5-ij)quinolinones of Structure I (compounds 6-71),compounds more simply referred to as imidazoquinolines areimidazoquinolinones or 5-aminoimidazoquinolines and5-aminoimidazoquinolinones. These particular compounds have been foundto be active in various central nervous system screens such ashypothermia and hypoxic stress tests and have been found to be dopamineand serotonin such as, 5HT_(1A) receptor binding assay antagonists.

The subject compounds are typically represented by Formula I wherein R₁,R₂ and R₃ are independently hydrogen, C₁₋₆ alkyl, C₃₋₅ alkenyl, C₃₋₅alkynyl, C₃₋₇ cycloalkyl, or C₄ -C₁₀ cycloalkyl- or phenyl-substitutedalkyl, or R₁ and R₂ are joined to form a C₃₋₇ cyclic amine which cancontain additional heteroatoms and/or unsaturation; X is hydrogen, C₁₋₆alkyl, halogen, hydroxy, alkoxy, cyano, carboxamide, carboxyl, orcarboalkoxyl; n is 0 or 1; and A is SO₂, N, CH, CH₂, CH-halogen, CHCH₃,C═O, C═S, C--SCH₃, C═NH, C--NH₂, C--NHCH₃, C--NHCOOCH₃, or C--NHCN; B isCH₂, CH, CH-halogen, O, C═O, N, NH or N--CH₃ ; n is 0 or 1; and D is CH,CH₂, CH-halogen, C═O, O, N, NH or N--CH₃.

Examples of "C₁ -C₆ alkyl" are methyl, ethyl, propyl, butyl, pentyl andhexyl and isomeric forms thereof.

Examples of "alkenyl" groups are C₃₋₅ straight or branched unsaturatedhydrocarbons having at least one double bond such as propenyl orbutenyl.

Examples of "alkynyl" groups are C₃₋₅ straight or branched unsaturatedhydrocarbons having at least one triple bond such as propynyl orbutynyl.

Examples of "C₃₋₇ cycloalkyl" are cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, or cycloheptyl. Examples of cycloalkyl-substituted alkylinclude (cyclopropyl)methyl, or (cyclobutyl)methyl. Examples ofphenyl-substituted alkyl include phenylmethyl (benzyl), 1-(phenyl)ethylor 2-(phenyl)ethyl, or 4-phenyl)butyl.

"C₃₋₇ cyclic amine" means where the R₁ and R₂ groups are joined to forma ring including the attached nitrogen atom, examples azetidine,pyrrolidine, piperidine, 2-methylpyrrolidine. This ring may also containadditional "hetero atoms" which are nitrogen, oxygen or sulfur and/orunsaturation, eg piperazine, N-methylpiperazine, morpholine, imidazole.

"Halogen" is defined as being any of F, Cl, Br or I.

"Akoxy" is defined as a C₁₋₆ alkyl group attached to an oxygen atom,such as methoxy, ethoxy, isopropoxy.

"Carboxamide" is defined as the group --CONH₂.

"Carbozlkoxyl" is defined as the group --COOR, where R is lower alkyl,such as carbomethoxy, carboethoxy.

"Thiocarbonyl" is defined as the group C═S, that is a carbonyl group inwhich the oxygen atom is replaced by sulfur.

"Sulfonyl" is defined as SO₂ in which the sulfur atom is attached to theadjacent ring atom groups.

"Pharmaceutically acceptable salts" are hydrochloride, hydrobromide,hydroiodide, sulfate, phosphate, acetate, propionate, lactate, maleate,malate, succinate, tartrate, cyclohexanesulfamates, methanesulfonates,ethanesulfonates, benzenesulfonates, toluenesulfonates and otherpharmaceutically acceptable counter ions for amines. Additionally, thecompounds of this invention may be administered in a suitable hydratedform.

The compounds of Formula I may be prepared from methyl-substitutedheterocycles of Formula II and substituted 3-aminotetrahydroquinolinesof Formula III following the general procedures described in Schemes1-7. Schemes and Formulas are shown below.

In Formula II, m is 0 or 1; when m is O then a double bond joins N to A.In Formula III, W is O or H₂ and D' may be nitro, amino, hydroxy oralkoxy; the remaining groups in Formulas II and III are as defined forI.

Some of the methyl substituted heterocycle intermediates required forthe work are described in the chemical literature as indicated.Literature procedures for the syntheses of 3-aminotetrahydroquinolineshave been reported and can be used to build the 8-substituted compoundsof Structure III required in this work; the compounds of Structure IIIwhere D' is nitro, amino, hydroxy or alkoxy are new compounds.

For the preparation of compounds III and for the conversion of compoundsII to I, malonate intermediates of Formula VI and VII are required. Forthe preparation of these compounds a malonic acid diester IV, preferablyth edimethyl, diethyl or methyl benzyl diester, is reacted with brominein carbon tetrachloride to afford the bromomalonic acid diester V. Thisis reacted with the appropriate amine in a suitable solvent such asmethylene chloride, ether, or tetrahydrofuran. After separating theamine hydrochloride by-product and removing any excess amine, thesubstituted aminomalonate of Formula VI may be used without furtherpurification, or may be purified by chromatography before further use.Amines which have been used in this reaction include dimethylamine,pyrrolidine, piperidine, morpholine, imidazole, 4-methylpiperazine,propylamine, and (R)-- and (S)--α-methylbenzylamine to give theintermediates VI listed in Table I. The mixed esters of Table 1(compounds VIi through VIq) are particularly useful, as thecarbobenzyloxy group can be removed by catalytic hydrogenation.Intermediates VId-h give tertiary amine products which can bedebenzylated by catalytic hydrogenation to the corresponding secondaryamine derivatives.

                  TABLE 1                                                         ______________________________________                                        Structures of Aminomalonates of Formula VI                                    Compound                                                                              Amine              R'       R"                                        ______________________________________                                        VIa     dimethylamine      ethyl    ethyl                                     VIb     dipropylamine      ethyl    ethyl                                     VIc     propylamine        ethyl    ethyl                                     VId     (phenylmethyl)methylamine                                                                        ethyl    ethyl                                     VIe     (phenylmethyl)propylamine                                                                        ethyl    ethyl                                     VIf     benzylamine        ethyl    ethyl                                     VIg     α-(1-phenylethyl)amine                                                                     ethyl    ethyl                                     VIh     (R)-α-(1-phenylethyl)amine                                                                 ethyl    ethyl                                     VIi     dimethylamine      methyl   benzyl                                    VIj     dipropylamine      methyl   benzyl                                    VIk     pyrrolidine        methyl   benzyl                                    VIm     piperidine         methyl   benzyl                                    VIn     morpholine         methyl   benzyl                                    VIp     imidazole          methyl   benzyl                                    VIq     4-methylpiperazine methyl   benzyl                                    ______________________________________                                    

When a primary amine is reacted with a compound of Formula V, theinitally formed product VI may be reacted with an acyl chloride, analkyl- or benzyl-chloroformate, or with di t-butyl dicarbonate to givethe amindes and carbamates of Formula VII. In formula VII, R₁ ' ishydrogen, alkyl, alkoxycarbonyl, or benzyloxycarbonyl; compoundsVIIe-VIIf (Table 2) have been prepared in this way from compound VIc.

Other aminomalonates of Formula VII may be prepared form dialkylaminomalonates such as diethyl aminomalonate VIII. Compound VIII reactswith di t-butyl dicarbonate to give carbamate VIIc, a versatileintermediate in which the amine function is protected with theacid-labile t-butoxycarbonyl group. Reductive alkylation of VIII withpropionaldehyde using sodium cyanoborohydride can be controlled so as togive secondary amine VIc or tertiary amine VIb as the major product.Compound VIc may be acylated with propionyl chloride to give VIIe orconverted to the t-butoxycarbonyl derivative VIIf.

                  TABLE 2                                                         ______________________________________                                        Formulas of Aminomalonates of Formula VII                                     Compound   R.sub.1 '   R.sub.2 R'   R"                                        ______________________________________                                        VIIa       H           H       ethyl                                                                              ethyl                                     VIIb       H           CH.sub.3                                                                              ethyl                                                                              ethyl                                     VIIc       OC(CH.sub.3).sub.3                                                                        H       ethyl                                                                              ethyl                                     VIId       C.sub.2 H.sub.5                                                                           H       ethyl                                                                              ethyl                                     VIIe       C.sub.2 H.sub.5                                                                           C.sub.3 H.sub.7                                                                       ethyl                                                                              ethyl                                     VIIf       OC(CH.sub.3).sub.3                                                                        C.sub.3 H.sub.7                                                                       ethyl                                                                              ethyl                                     ______________________________________                                    

The 2,3,6,7-tetrahydro-1H,5H-benzo(ij)quinolizin-2-amines of theinvention, compounds of Formula I where A, B, and D are CH₂ may beprepared as shown in Scheme 1 for the preparation of compounds 1-5.

Bromination of 8-methylquinoline (IX) with N-bromosuccinimide afforded8-(bromomethyl)quinoline (X) which was reacted with diethyl(formylamino)malonate (VIIa) to give XIa (R₁ '═H). This was hydrogenatedusing a platinum catalyst to give XIIa which was hydrolyzed to XIIIa.This was hydrolyzed to XIV, methylated to XV, and reduced to givecompound 1. Compound XIIIa was also reduced with lithium aluminumhydride to give a mixture of compounds 2 and 3. The propylaminoanalogues, compounds 4 and 5, were prepared as outlined in Scheme 1 from8-(bromomethyl)quinoline and diethyl (1-oxopropyl)malonate (VIId).

Analogues may be prepared by substituting aminomalonates VIi-VIq forVIIa and VIId in the above reaction sequence.

The 5,6-dihydro-N,N-dipropyl-4H-imidazo(4,5,1-j)quinolin-5-amines of theinvention, compounds of Formula I where D is nitrogen, A is CH, n is 0and D and A are joined by a double bond, may be prepared as illustratedin Scheme 2 for the preparation of compound 6. Catalytic hydrogenationof 2-methyl-6-nitroaniline (XVI) using a palladium catalyst afforded3-methyl-1,2-benzenediamine (XVIII) which was heated with formic acid togive 4-methylbenzimidazole (XVIII). This was heated in dioxane withdi-t-butyl dicarbonate and the t-butyl4-methylbenzimidazole-1-carboxylate (XIXa, R is OC(CH₃)₃) thus obtainedwas brominated with N-bromosuccinimide in carbon tetrachloride to givet-butyl 4-(bromomethyl)benzimidazole-1-carboxylate (XXa). Alkylation ofXXa with the potassium salt of diethyl (dipropylamino)-malonate (VIb) inrefluxing THF afforded XXIa which was hydrolyzed to XXII using sodiumethoxide in ethanol containing limited amounts of water. Compound XXIIwas reduced to the alcohol XXIII using lithium aluminum hydride. WhenXXIII was treated with carbon tetrabromide and triphenylphosphine inmethylene chloride compound 6 was obtained directly.

Modifications may be made in this reaction sequence. The hydrolysis ofXXIa to XXII may be carried out in two steps; under mild hydrolysisconditions, ethyl-α-(dipropylamino)-1H-benzimidazol-4-propanoate, formedby loss of the t-butoxycarbonyl group, can be obtained as the onlyreaction product, and this may be subsequently hydrolyzed to XXII.Compound XVIII was reacted with methyl chloroformate to give XIXb (R isOCH₃) which was converted to high yield to XXII as shown in Scheme 2.Acetylation of XVIII gave XIXc (R is CH₃) which was also converted toXXII, although the yield in this reaction was not as high as when thet-butoxycarbonyl or carbomethoxy protecting groups were used.

The reaction sequence of Scheme 2 may be used to prepare analogues inwhich the dipropylamine substituent is modified. Using the malonatesVIi-VIq in place of diethyl (dipropylamino)malonate (VIb), compounds7-12 were obtained. In the preparation of these compounds the adductformed by reacting the malonate with XXa was converted to the methylα-(substituted amino)-1H-benzimidazole-4-propanoate by hydrogenolysis asdescribed in Example 19.

The sequence may also be used to prepare compounds of Formula I whichhave a substituent (X) in the benzene ring. For example, using thesubstituted benzimidazoles, 5-methoxy-4-methylbenzimidazole,6-methoxy-4-methylbenzimidazole, 4-methoxy-6-methylbenzimidazole and5-chloro-4-methylbenzimidazole in place of 4-methylbenzimidazole(XVIII), compounds 14-18 were obtained. Compounds 14-16 were treatedwith hydrobromic acid to give the corresponding phenols 19-21respectively.

An alternate synthesis of5,6-dihydro-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amines from3-aminoquinoline (XXIV) is shown in Scheme 3. Compound XXIV wasformylated to give XXV and this was hydrogenated using platinum oxide ascatalyst and formylated to give XXVI in good yield. Bromination of XXVIgave the 6-bromo compound XXVII which was nitrated to give XXVIII.Hydrogenation of XXXIX in presence of palladium charcoal gave thetriamine XXX, which was treated with formic acid to give compound 22.The primary amine reacted with propionaldehyde and sodiumcyanoborohydride to give the mono- and di-propylamine derivatives,compounds 23 and 6 respectively. Catalytic reduction of compound 22 inthe presence of formaldehyde gave the previously described dimethylamineanalogue (compound 7).

The sequence of Scheme 3 may also be used to prepare compounds ofFormula I which have a substituent (X) in the benzene ring. For example,using 3-amino-6-methylquinoline in place of 3-aminoquinoline, compound24 was obtained. The 3-amino-6-methylquinoline intermediate was preparedusing literature procedures from p-toluidine and the sodium salt ofnitromalonaldehyde. Other ring-substituted analogues can be prepared bythis procedure.

The 5-amino-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2-ones of theinvention, compounds where A is carbonyl, n is O, and D is NH orN-(lower alkyl) may be prepared as shown in Scheme 4. NitroquinolineXXIX, prepared as outlined in Scheme 3, was protected, reduced, andcyclized using phosgene to give the t-butoxycarbonyl-protectedimidazoquinolinone XXXIII. This was hydrolyzed to the amine (compound26) which was alkylated to give the dimethylamino analogue compound 27and propylamino analogues, compounds 28 and 29. Further alkylation ofcompounds 27 and 29 using potassium hydride/methyl iodide gave compounds30 and 31 respectively.

6-Bromo-1,2,3,4-tetrahydro-3-quinolinamine (compound XXIX) was alkylatedwith propyl iodide to give XXIVa and this was reducedto-1,2,3,4-tetrahydro-N³,N³ -dipropyl-3,8-quinolinediamine, FormulaXXXVa where R₁ and R₂ are C₃ H₇. Alkylation of XXIX withformaldehyde/formic acid following by catalytic reduction gave thecorresponding dimethylamino compound Formula XXXVb where R₁ and R₂ areCH₃. Compound XXXVa has also been prepared from 2-nitrobenzylchloride inExample 67.

Intermediates XXXII, XXXVa and XXXVb may be used for the preparation ofthe 5-amino-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolines and5-amino-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2-ones of the inventionand in the preparation of a variety of new heterocyclic analogues wherethe adjacent nitrogen atoms are joined to form a five or six memberedheterocyclic ring as shown for compound XXXVa in Scheme 5. CompoundXXXVa was reacted with thiophosgene or di-(2-pyridyl)thiocarbonate togive 5-(dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2-thione (compound 33) which was further alkylated to5,6-dihydro-2-methylthio-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinoline-5-amine(compound 34). Compounds XXXVa reacted with cyanogen bromide to givecompound 35 which was alkylated with methyl iodide to give compound 36.Compound XXXVa reacted with diphenyl cyanocarbonimidate to give compound37 and with sulfamide to give compound 38.

Compound with a six-membered heterocyclic ring were prepared by reactingcompound XXXVa with ethyl bromoacetate to give compound 39, chloroaceticanhydride to give compound 40, butyl glyoxylate to give compound 41,ethyl oxalyl chloride or oxalyl chloride to give compound 42, ethylbromopropionate to give compound 84, and α-chloropropionyl chloride togive compound 85.

A similar series of compounds (compounds 43-50) were prepared from1,2,3,4-tetrahydro-N³,N³ -dimethyl-3,8-quinolinediamine; other productsmay be obtained by substituting compound XXXII in these reactions.

The 5-amino-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2-ones of theinvention may also be prepared by the route shown in Scheme 6.3-Methyl-1,2-benzenediamine is reacted with carbonyl diimidazole orphosgene to give 4-methylbenzimidazolone (XXXVI). This is refluxed withphosphorus oxychloride to give XXXVII which is protected and reactedwith N-bromosuccinimine to give compound XXXIX. This is coupled withVIIb and the resulting adduct LX is hydrolyzed to LI. Reduction withlithium aluminum hydride alcohol LXII which was treated with carbontetrabromide/triphenylphosphine to give compound 51. Compound 51 wasrefluxed in acetic acid to effect conversion to compound 6.

Analogues of compounds 51 and 6 may be prepared by the procedure ofScheme 6. By using malonates VIk-q or VIg in place of VIIc, compounds52-57 were prepared.

The sequence may also be used to prepare compounds of Formula I whichhave a substituent (X) in the benzene ring. For example, using thesubstituted benzimidazoles 2,5-dichloro-4-methylbenzimidazole,2-chloro-5-methoxy-4-methylbenzimidazole,2-chloro-6-methoxy-4-methylbenzimidazole and2-chloro-4-methoxy-6-methylbenzimidazole in place of2-chloro-4-methylbenzimidazole (XVIII) compounds 58-63 were obtained;these compounds have also been prepared from the ring substituted1,2,3,4-tetrahydro-3,8-quinolinediamines as described in Examples 82-87.

Compounds with a methyl substituent at position 6 in theimidazoquinoline or imidazoquinolinone ring were prepared from4-ethylbenzimidazole by the procedure of Scheme 2 (see Example 88) andby converting 2-ethylaniline to 1,2,3,4-tetrahydro-4-methyl-N³,N³-dimethyl-3,8-quinolinediamine using the procedure of Scheme 7 and 4.Compounds with an alkyl substituent at position 4 in theimidazoquinoline or imidazoquinolinone ring were prepared fromintermediate XXIII and related primary alcohols by oxidation to thealdehyde, reacting the aldehyde with an alkyl magnesium bromide, andcyclizing the resulting alcohol (see Example 92). Following theseprocedures, compounds 64-71 were obtained.

The 5-amino-5,6-dihydro-4H-oxazolo(5,4,1-ij)quinolin-2-ones of theinvention, compounds where A is carbonyl, n is 0 and D is 0, may beprepared as outlined in Scheme 7 for the preparation of compound 72.3-Methyl-2-nitroanisole (XLIII) was reduced to XLIV and this wasrefluxed with acetic anhydride to give XLV. This product was brominatedand coupled with VIb to give XLVII. Compound XLVII was refluxed withsodium ethoxide in ethanol to give XLVIII which was converted to thephenol XLIX and reduced with lithium aluminum hydride to L. Compound Lwas treated with carbonyl diimidazole to give compound 72.

The related compounds 73-79 were prepared by the procedure of Scheme 7from compound XLVI and the appropriate malonate of Formula VI or VII.Compounds 80 and 82 were prepared by reacting phenol intermediate L withthiophosgene or ethyl bromoacetate.

Compounds 86-93, were prepared from the 4-methyl heterocycle of FormulaII by the procedures described in Schemes 2 and 6.

Compounds 95-97 were prepared from5-(propylamino)-5,6-dihydro-4H-pyrrolo (3,2,1-ij)quinolin-2,3-dione(compound 94) which was prepared as described in Example 118.

6-(Dipropylamino)-2,3,6,7-tetrahydro-5H-pyrido(3,2,1-ij)quinazolin-3-one(compound 98) was prepared in nine steps from 3-methyl-2-nitrobenzoicacid as described in Example 122. Compounds 99-105 were prepared fromthe same starting material using the procedures described in Examples123-129.

An alternative procedure for synthesizing the compounds of the inventionis shown in Scheme 8. t-Butyl1,2,3,4-Tetrahydro-5-(dipropylamino)quinoline-1-carboxylate prepared asdescribed in Example 130 is converted to the anion LI which is furtherreacted as shown in Scheme 8 to yield compounds 87, 92, 95, 97 and 102.The compounds of the invention can be separated by conventional methodsinto R- and S- isomers; the invention includes both racemic andoptically pure products. Resolution can be accomplished using resolvingagents such as optically active dibenzoyltartaric acid, camphorsulfonicacid, bis-o-toluoyltartaric acid, tartaric acid, and diacetyl tartaricacid.

A second procedure useful in resolving primary and secondary aminecompounds of Formula I involves their conversion to diastereomericamides using an optically active acid. The diastereomeric amides areseparated and the amide bond is cleaved to afford the optically pureFormula I compounds. This procedure is illustrated in Examples 49 and 50for the preparation of the optical isomers of compound 29 usingt-butoxycarbonyl-L-phenylalanine as the resolving agent. For theresolution, racemic compound 26 was coupled tot-butoxycarbonyl-L-phenylalanine and the diastereomeric amide productswere separated by chromatography into the (+) and (-) forms; each isomerwas carried forward as described in detail for the "(-) isomer" below.The (-) isomer was reacted with trifluoracetic acid to give (-)N-(5,6-dihydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)-L-phenylalanineamide.Edman degradation of this compound, by reaction with phenylisothiocyanate followed by trifluoracetic acid, removed thephenylalanine residue and afforded the (-) form of compound 26. Furtherreaction of this product with propionaldehyde and sodiumcyanoborohydride gave the (-) form of compound 29, the more activeisomer.

Compounds where the R₃ substituent is alkyl exist as diastereomers inwhich the alkyl group and amine substituent (NR₁ R₂) can be cis or transto one another. The invention includes the use of such compounds as theisomer mixture (RR, RS, SR SS), the racemic diastereomers (R,R and S,S;or R,S and S,R) and the optically pure diastereomer. The diastereomermixture can be separated by conventional means, e.g. by silica gelchromatography. The racemic diastereomers thus obtained may be resolvedinto optically pure compounds using the procedures described above.

The compounds listed below were tested and found to have possible usefulantipsychotic activity properties as indicated by their having CNSactivity (ED₅₀ numbers of less than 50 mg/kg values) in the knownhypothermia and/or hypoxic stress tests; several of the compounds havealso shown analgesic activity. For these tests, groups of 4 male CF-1mice are dosed ip (sc in the hypoxic stress and HCl writhing tests) withsuspensions or solutions in 0.25% aqueous methylcellulose. Doses of thecompound under study began at 100 mg/kg and were decreased at a 0.3 loginterval until no responders were obtained. The procedure described bySpearman and Karber, Finney, D. J. "Statistical Methods in BiologicalAssay", Chapter 20, was used to calculate the ED₅₀ and 95% confidenceintervals.

In the hypothermia test, abdominal temperature was measured after 45minutes. Mice with temperatures more than 2 standard deviations belowthe mean are hypothermic. This test is used to identify compounds whichmay be useful as antipsychotics or as hypotensives.

In the hypoxic stress test, following compound administration the micewere placed individually in stoppered 125 ml Erlenmeyer flasks 30 minafter receiving the test agent. The survival time is recorded. Micesurviving more than the mean +2 standard deviations in parallel runcontrols are scored as showing a drug effect. This test is used toidentify compounds which may be useful as anxiolytics.

For determination of analgesic activity, thirty minutes after testcompound injection, the mice were injected i.p with 0.15% HCl, 10 ml/kg.Mice were then placed in plastic boxes and observed for fifteen minutesto record the number of animals failing to writhe. If at least three ofthe mice receiving the test compound failed to writhe, the compound wasretested at lower dose levels.

In the hypothermia and hypoxic stress tests, compounds of the inventionhave been found more potent than related compounds, showing ED_(50's)values as low as 0.05 mg/kg. The compounds also had good activity in thehypothermia test when the animals were dosed orally with the drug.

The dosage regimen for treating patients with the compounds of thisinvention is selected in accordance with a variety of factors includingthe type, age, weight, sex, and medical condition of the patient, theseverity of the psychosis, the route of administration and theparticular compound employed. An ordinarily skilled physician orpsychiatrist will readily determine and prescribe the effective amountof compound to prevent or arrest the progress of the condition. In soproceeding, the physician or psychiatrist could employ relatively lowdosages at first, subsequently increasing the dose until a maximumresponse is obtained.

Initial dosages of the compounds of the invention are ordinarily in thearea of at least 10 mg up to about 1200 mg per day orally, which may begiven in a single dose or in multiple doses. When other forms ofadministration are employed equivalent doses are administered. Whendosages beyond 600 mg are employed, care should be taken with eachsubsequent dose to monitor possible toxic effects.

The compounds of this invention are administered in oral unit dosageforms such as tablets, capsules, pills, powders, or granules. They mayalso be introduced parenterally, (e.g., subcutaneously, intravenously,or intramuscularly), using forms known to the pharmaceutical art. Theyalso may be administered rectally or vaginally in such forms assuppositories or bougies. In general, the preferred route ofadministration is oral.

The compounds of this invention can also be administered aspharmaceutically or therapeutically acceptable salt such ashydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate,propionate, lactate, maleate, malate, succinate, tartrate,cyclohexanesulfamates, methanesulfonates, ethanesulfonates,benzenesulfonates, toluenesulfonates and the like. Additionally, thecompounds of this invention may be administered in a suitable hydratedform.

EXAMPLE 1 Benzyl methyl malonate

A mixture of dimethyl malonate (100 g, 0.75 mol) and benzyl alcohol (108g, 1.0 mol) was heated for 2 h at 180° C. under a distillation head soas to remove the methanol generated in the reaction. The product wasthen distilled under reduced pressure to give a forerun of 55 g (amixture of dimethyl malonate and benzyl alcohol) followed by 63 g (40%)of benzyl methyl malonate, bp 105°-115° C./0.2 mm (98% pure by GC). Thepot residue consisted of 71 g (33%) of dibenzyl malonate (90% pure byGC).

EXAMPLE 2 Benzyl methyl bromomalonate

Bromine (17.6 g, 0.11 mol) was added to a stirred solution of benzylmethyl malonate (20.8 g, 0.10 mol) in carbon tetrachloride. After 30minutes the solvent was removed under reduced pressure to give 28 g ofproduct (85% pure by gc, containing 7% benzyl methyl malonate) which wasused without further purification.

EXAMPLE 3 Diethyl (dipropylamino)malonate (compound VIb)

Dipropylamine (22.3 g, 0.22 mol) was added to a stirred solution ofdiethyl bromomalonate (47.8 g, 0.20 mol) in THF (400 mL) and thesolution was stirred for 18 hours at room temperature. The precipitateof dipropylamine hydrobromide was filtered off and washed with THF. TheTHF phase was evaporated and the residual oil was partitioned betweenethyl acetate (200 mL) and sodium hydroxide solution (10 mL of 4 N). Theethyl acetate phase was separated, washed with water (2×10 mL), and thesolvent was removed under reduced pressure. The residual oil wasdissolved in an equal volume of hexane and was applied to a silica gelcolumn (420 g) which was eluted initially with ethyl acetate:hexane(1:20). The concentration of ethyl acetate in the eluant was increasedslowly until all the diethyl (dipropylamino)malonate was eluted from thecolumn. Fractions containing the compound as determined by TLC and GCwere pooled and the solvent was removed to give diethyl(dipropylamino)malonate as an oil in 80-90% yield.

Compounds VIa and VIc-VIh were obtained using this procedure, butsubstituting dimethylamine, propylamine, N-methylbenzylamine,N-propylbenzylamine, benzylamine, α-methylbenzylamine,(R)-α-methylbenzylamine for dipropylamine.

Compounds VIi-VIp were obtained using this procedure, but substitutingbenzyl methyl bromomalonate for diethyl bromomalonate and usingdimethylamine, dipropylamine, pyrrolidine, piperidine, morpholine,4-methylpiperazine and imidazole as the amine reaction component.

EXAMPLE 4 Diethyl (N-(1,1-dimethylethoxycarbonyl)propylamino)malonate(compound VIIf)

Diethyl aminomalonate (21.1 g, 0.1 mol) was dissolved in ethanol andsodium ethoxide in ethanol (50 mL of 1 M) was added. Propionaldehyde(6.6 g, 0.11 mol) and sodium cyanoborohydride (3.6 g, 0.058 mol) wereadded to the stirred solution. After 30 minutes additionalpropionaldehyde (6.0 g) and sodium cyanoborohydride (2.6 g) were addedto complete the reaction. The solution was evaporated, and the residuewas partitioned between ethyl acetate and water. Evaporation of theethyl acetate gave 25.1 g of diethyl (propylamino)malonate. This wasmixed with di t-butyl dicarbonate (34 g, 0.156 mol) and the mixture washeated at 100° C. for 1 hour. The crude product was chromatographed onsilica gel using ethyl acetate:hexane as the eluant to give 21.2 g ofdiethyl (N-(1,1-dimethylethoxycarbonyl)propylamino)malonate as an oil.

Compound VIIe was obtained by following the same procedure, butsubstituting propionyl chloride for di t-butyl dicarbonate.

EXAMPLE 5 Diethyl (1-oxopropyl)malonate (compound VIId)

Triethylamine (20 g, 0.2 mol) and propionic anhydride (12.54 g, 0.096mol) were added to diethyl aminomalonate hydrochloride (20.40 g, 0.096mol) in THF (300 mL) and the reaction was stirred at room temperaturefor 45 minutes. The solvent was removed under reduced pressure and thecrude product was partitioned between ethyl acetate and water. The ethylacetate phase was separated and evaporated to give 34.64 g of whitesolid. This was dissolved in hot ethyl acetate (60 mL), hexane (60 mL)was added, and the solution was filtered to remove insoluble material.The solution was cooled to -10° C. and filtered to give 17.63 g (72%) ofdiethyl (1-oxopropyl)malonate, mp 89°-93° C.

Compound VIIc was obtained by following the same procedure, butsubstituting di t-butyl dicarbonate for propionic anhydride.

EXAMPLE 6 8-(Bromomethyl)quinoline (compound X)

A mixture of 8-methylquinoline (45 g, 0.314 mol), N-bromosuccinimide (55g, 0.309 mol) and benzoyl peroxide (1.5 g) in carbon tetrachloride (250mL) was refluxed for 7 hours. The reaction was filtered and evaporated,and the crude product was crystallized from methanol (70 mL) to give37.7 g of product. The mother liquors were chromatographed on silica gelin chloroform to give 17 g of material which was crystallized from ethylacetate:hexane to give an additional 12.0 g of product.

EXAMPLE 7 Diethyl (formylamino)(8-quinolinylmethyl)propanedioate(compound XIa)

Diethyl (formylamino)malonate (22.0 g, 0.108 mol) was added to a stirredsolution of sodium ethoxide in ethanol (prepared from 2.4 g of sodiumand 250 mL of ethanol, 0.10 mol). After 5 min, 8-(bromomethyl)quinoline(22.0 g, 0.10 mol) was added and the solution was stirred for anadditional 15 minutes. The solvent was removed under reduced pressureand the product was partitioned between ethyl acetate and water. Theethyl acetate was removed and the residual oil was crystallized fromether to give 19.9 g (58%) of diethyl(formylamino)(8-quinolinylmethyl)propanedioate, mp 120°-122° C. Anal.Calcd. for C₁₈ H₂₀ N₂ O₅ : C, 62.78; H, 5.85; N, 8.14. Found: C, 62.53;H, 6.03; N, 8.07.

EXAMPLE 8N-(2,3,6,7-Tetrahydro-3-oxo-1H,5H-benzo(ij)quinolizin-2-yl)-formamide(compound XIIIa)

Part A. Ethyl2,3,6,7-tetrahydro-3-oxo-2(formylamino)-1H,5H-benzo(ij)quinolizine-2-carboxylate(compound XIIa)

A mixture of diethyl (formylamino)(8-quinolinylmethyl)malonate (9.2 g,26.7 mmol) and platinum oxide (0.7 g) in glacial acetic acid (150 mL)was hydrogenated (50 lb initial pressure) for 15 minutes (hydrogenuptake ca. 2 equiv). The mixture was filtered through celite and thesolvent removed under reduced pressure. The product was partitionedbetween ethyl acetate and sodium hydroxide solution. The ethyl acetatephase was washed with water, the ethyl acetate was evaporated, and theproduct was crystallized from ether to give 7.8 g (97%) of ethyl2,3,6,7-tetrahydro-3-oxo-2-(formylamino)-1H,5H-benzo(ij)quinolizine-2-carboxylate,mp 103°-106° C. Anal. Calcd. for C₁₆ H₁₈ N₂ O₄ : C, 63.56; H, 6.00; N,9.27. Found: C, 63.51; H, 6.09; N, 9.18.

Part B.N-(2,3,6,7-Tetrahydro-3-oxo-1H,5H-benzo(ij)quinolizin-2-yl)formamide(compound XIIIa)

Sodium hydroxide solution (5.0 mL of 4.0 N, 20 mmol) was slowly added toethyl2,3,6,7-tetrahydro-3-oxo-2-(formylamino)-1H,5H-benzo(ij)quinolizine-2-carboxylate(3.04 g, 10.0 mmol) in methanol (25 mL). After stirring at roomtemperature for 30 min, hydrochloric acid (5.0 mL of 4.0 N) was addedand the precipitate was filtered off, washed with water and air dried togive 2.4 g ofN-(2,3,6,7-tetrahydro-3-oxo-1H,5H-benzo(ij)quinolizin-2-yl)formamide, mp149°-152° C. A portion of the product was recrystallized from ethylacetate for analysis; mp 140°-143°. Anal. Calcd. for C₁₃ H₁₄ N₂ O₂ : C,67.81; H, 6.13; N, 12.17. Found: C, 67.67; H, 6.07; N, 11.94.

EXAMPLE 92,3,6,7-Tetrahydro-N,N-dimethyl-1H,5H-benzo(ij)quinolizin-2-amine(Compound 1)

Part A. 2,3,6,7-Tetrahydro-3-oxo-1H,5H-benzo(ij)quinolizin-2-amine(compound XIV)

A solution ofN-(2,3,6,7-tetrahydro-3-oxo-1H,5H-benzo(ij)quinolizin-2-yl)-formamide(0.8 g, 3.4 mmol) in ethanolic hydrogen chloride (10 mL of 4.2 M) washeated at 50° C. for 2 hours. The ethanol was cooled, an equal volume ofether was added, and the precipitate was filtered off and washed withether to give 0.78 g of2,3,6,7-tetrahydro-3-oxo-1H,5H-benzo(ij)quinolizin-2-aminehydrochloride, mp 216°-221° C. The product was recrystallized foranalysis; mp 219°-222° C. Anal. Calcd. for C₁₂ H₁₄ N₂ O.HCl: C, 60.37;H, 6.33; Cl, 14.85; N, 11.74. Found: C, 59.89; H, 6.42; Cl, 15.41; N,11.68.

Part B.2,3,6,7-Tetrahydro-N,N-dimethyl-1H,5H-benzo(ij)quinolizin-2-amine(compound 1)

A mixture of 2,3,6,7-tetrahydro-3-oxo-1H,5H-benzo(ij)quinolizin-2-amine(2.0 g), 30% formaldehyde solution (1 mL) and 10% palladium/carbon (0.5g) in ethanol (150 mL) was hydrogenated (50 lb initial hydrogenpressure) until uptake of hydrogen was complete (2 hours). The solutionwas filtered to remove the catalyst, evaporated, the crude product wasdissolved in ether (300 mL) and lithium aluminum hydride (1.5 g) wasadded. After 1 hour, ethyl acetate was added, the solvents were removedunder reduced pressure, and the product was partitioned between ethylacetate and water. Evaporation of the ethyl acetate gave an oil whichwas purified by chromatography on silica gel to give 1.03 g of2,3,6,7-tetrahydro-N,N-dimethyl-1H,5H-benzo(ij)-quinolizin-2-amine.

The bulk of the product was converted to the maleate salt, mp 135°-137°C. from methanol:ether. A sample was recrystallized for analysis; mp135°-137° C. Anal. Calcd. for C₁₄ H₂₀ N₂.C₄ H₄ O₄ : C, 65.04; H, 7.28;N, 8.43. Found: C, 64.72; H, 7.43; N, 8.20.

EXAMPLE 10 2,3,6,7-Tetrahydro-N-methyl-1H,5H-benzo(ij)quinolizin-2-amineand N-Ethyl-2,3,6,7-tetrahydro-N-methyl-1H,5H-benzo(ij)quinolizin-2-amine (Compounds 2 and 3)

N-(2,3,6,7-Tetrahydro-3-oxo-1H,5H-benzo(ij)quinolizin-2-yl)formamide (4g, 0.017 mol) was added in 0.5 g aliquots every 10 min to a stirredsolution of lithium aluminum hydride (2.77 g, 0.073 mol) in anhydrousether (500 mL). After stirring overnight at room temperature thereaction was refluxed for 3 hours, cooled on ice and quenched with ethylacetate and methanol. The solvent was evaporated under reduced pressureand the crude product was partitioned between ethyl acetate (800 mL) andwater (40 mL). The ethyl acetate was separated, washed with water, andthe ethyl acetate was evaporated to give 3.64 g of crude product. Theproducts were separated by chromatography on silica gel in chloroform togive, as the first product eluted from the column, 1.4 g ofN-ethyl-2,3,6,7-tetrahydro-N-methyl-1H,5H-benzo(ij)-quinolizin-2-amine.The compound was converted to the maleate salt, mp 90°-100° C. frommethanol:ether. The product was recrystallized for analysis; mp 94°-98°C. Anal. Calcd. for C₁₅ H₂₂ N₂.C₄ H₄ O₄ : C, 65.87; H, 7.57; N, 8.09.Found: C, 65.53; H, 7.81; N, 8.08.

Continued elution of the column gave 1.3 g of2,3,6,7-tetrahydro-N-methyl-1H,5H-benzo(ij)quinolizin-2-amine which wasconverted to the maleate salt, mp 151°-155° C. from methanol:ether.Anal. Calcd. for C₁₃ H₁₈ N₂.C₄ H₄ O₄ : C, 64.13; H, 6.97; N, 8.80.Found: C, 63.79; H, 7.16; N, 8.62.

EXAMPLE 11 Diethyl ((1-oxopropyl)amino)(8-quinolinylmethyl)propanedioate(compound XIb)

Diethyl (1-oxopropyl)malonate (15.14 g, 0.065 mol) was added to astirred solution of sodium ethoxide in ethanol (165 mL of 0.4 M, 0.066mol). After 5 minutes, 8-(bromomethyl)quinoline (13.15 g, 0.059 mol) wasadded and the solution was stirred for an additional 15 minutes. Thesolvent was removed under reduced pressure and the product was dissolvedin ethyl acetate (300 mL) which was washed with water (3×10 mL). Theethyl acetate was removed and the residual solid (27.3 g) wascrystallized from ethyl acetate:hexane to give 21.6 g of tan crystals,mp 80°-100° C. Recrystallization of an aliquot (4 g) from ethylacetate:hexane gave 2.87 g of tan crystals, mp 104°-106° C. Anal. Calcd.for C₂₀ H₂₄ N₂ O₅ : C, 64.50; H, 6.50; N, 7.52. Found: C, 64.25; H,6.51; N, 7.51.

EXAMPLE 12 Ethyl 2,3,6,7-tetrahydro-3-oxo-2-((1-oxopropyl)amino)-1H,5H-benzo(ij)quinoliz-ine-2-carboxylate (compound XIIb).

A mixture of diethyl((1-oxopropyl)amino)(8-quinolinylmethyl)-propanedioate (17.47 g, 0.047mol) and platnium oxide (0.72 g) in glacial acetic acid (150 mL) washydrogenated (50 lb initial pressure) until hydrogen uptake ceased (1.8equiv). The mixture was filtered through celite and the solvent removedunder reduced pressure. The product was crystallized from ethyl acetateto give 12.08 g of crystals, mp 136°-140° C. A sample was recrystallizedfrom ethyl acetate for analysis; mp 137°-141° C. Anal. Calcd. for C₁₈H₂₂ N₂ O₄ ; C, 65.44; H, 6.71; N, 8.48. Found: C, 65.66; H, 6.64; N,8.43.

EXAMPLE 13N-(2,3,6,7-Tetrahydro-3-oxo-1H,5H-benzo(ij)quinolizin-2-yl)-propanamide(compound XIIIb)

Sodium hydroxide solution (10 mL of 4.0 N, 0.04 mol) was slowly added toethyl2,3,6,7-tetrahydro-3-oxo-2-((1-oxopropyl)amino)-1H,5H-benzo(ij)quinolizine-2-carboxylate(3.33 g, 0.010 mol) in methanol (50 mL). After stirring at roomtemperature for 30 minutes, the solvent was removed under reducedpressure. The resulting solid was dissolved in water (20 mL) andmethanol (trace), neutralized with 4N HCl (10 mL, 0.04 mol), cooled to-10° C., and the precipitate was filtered off and air dried to give 2.86g of2,3,6,7-tetrahydro-3-oxo-2-((1-oxopropyl)amino)-1H,5H-benzo(ij)quinolizine-2-carboxylicacid. This was refluxed in ethanol for 20 minutes to effectdecarboxylation. The ethanol was removed under reduced pressure and thesolid was crystallized from ethyl acetate:hexane to give 1.85 g ofN-(2,3,6,7-tetrahydro-3-oxo-1H,5H-benzo(ij)quinolizin-2-yl)propanamide,mp 149°-152° C. A sample was recrystallized for analysis; mp 152°- 154°C. Anal. Calcd. for C₁₅ H₁₈ N₂ O₂ : C, 69.74; H, 7.02; N, 10.85. Found:C, 69.33; H, 7.33; N, 10.68.

EXAMPLE 14 2,3,6,7-Tetrahydro-N-propyl-1H,5H-benzo(ij)quinolizin-2-amine(compound 4)

N-(2,3,6,7-Tetrahydro-3-oxo-1H,5H-benzo(ij)quinolizin-2-yl)propanamide(2.5 g, 0.01 mol) was dissolved in anhydrous ether (500 mL). Thesolution was cooled to 0° C., lithium aluminum hydride (1.46 g, 0.038mol) was added and the reaction was refluxed for 4 hours. The reactionwas quenched with ethyl acetate and methanol, the solvents were removedunder reduced pressure and the material was partitioned between ethylacetate (400 mL) and water (50 mL). Evaporation of the ethyl acetatephase gave 2.35 g of yellow oil. The product was purified bychromatography on silica gel. Elution of the column with 1% and 2.5%methanol:chloroform gave 2.07 g of2,3,6,7-tetrahydro-N-propyl-1H,5H-benzo(ij)quinolizin-2-amine.

The bulk of the product was converted to the hemifumarate salt which wasrecrystallized from methanol:ether; mp 190°-194° C. Anal. Calcd. for C₁₅H₂₂ N_(21/2) C₄ H₄ O₄ : C, 70.80; H, 8.39; N, 9.71. Found: C, 70.37; H,8.26; N, 9.65.

EXAMPLE 152,3,6,7-Tetrahydro-N,N-dipropyl-1H,5H-benzo(ij)quinolizin-2-amine(compound 5)

A mixture of2,3,6,7-tetrahydro-N-propyl-1H,5H-benzo(ij)quinolizin-2-amine (2.33 g,0.01 mol), propyl iodide (5.16 g, 0.03 mol) and anhydrous potassiumcarbonate (3 g, 0.02 mol) in dimethylformamide (75 mL) was stirred for 5hours at 90° C. At this time additional propyl iodide (1.72 g, 0.01 mol)and potassium carbonate (0.05 g, 0.0036 mol) were added and the reactionwas continued for an additional 2 hours. The reaction was cooled,filtered to remove inorganic material, and the solvent was removed underreduced pressure. The product was partitioned between ethyl acetate (800mL) and 4N sodium hydroxide (20 mL, 0.08 mol), the organic layerconcentrated, filtered, and chromatographed on silica gel in 5-30% ethylacetate:hexane to give 2.19 g of2,3,6,7-tetrahydro-N,N-dipropyl-1H,5H-benzo(ij)quinolizin-2-amine.

A portion of the product was converted to the fumarate salt, mp112.5°-116° C. Recrystallization from methanol:ether gave light browncrystals, mp 112°-116° C. Anal. Calcd. for C₁₈ H₂₈ N₂.C₄ H₄ O₄ : C,68.01; H, 8.30; N, 7.21. Found: C, 67.73; H, 8.47; N, 7.14.

EXAMPLE 16 4-Methyl-1H-benzimidazole (compound XVIII)

Part A 3-Methyl-1,2-benzenediamine (compound XVII)

2-Methyl-6-nitroaniline (15.2 g, 0.1 mol) was dissolved by heating inethanol (150 mL). The solution was cooled, 10% palladium on carbon (1.0g) was added and the solution was hydrogenated (50 lb initial hydrogenpressure) until uptake of hydrogen ceased (1 hour). The catalyst wasfiltered off and the ethanol was removed under reduced pressure to give11.9 g (98%) of 3-methyl-1,2-benzenediamine as a solid which was usedwithout purification.

Part B. 4-Methyl-1H-benzimidazole (Compound XVIII)

A mixture of 3-methyl-1,2-benzenediamine (11.9 g) and formic acid (150mL) was heated at 70° C. for 15 minutes. The solvent was removed underreduced pressure and the residual oil was stirred with water (100 mL)and sodium hydroxide solution (65 mL of 4.0 N) was added until thesolution was just basic. The precipitate was filtered off, washed withwater, and air dried to give 11.6 g (90%) of 4-methyl-1H-benzimidazole,mp 141°-145° C.

EXAMPLE 17 t-Butyl 4-(bromomethyl)-1H-benzimidazole-1-carboxylate(compound XXa)

Part A. t-butyl 4-methyl-1H-benzimidazole-1-carboxylate (compound XIXa)

A mixture of 4-methyl-1H-benzimidazole (11.6 g, 0.088 mol) and dit-butyl dicarbonate (21.1 g, 0.097 mol) was heated at 80° C. in dioxane(200 mL) for 1 hour. The solvent was removed under reduced pressure andthe residual oil (24.3 g) was chromatographed on silica gel using ethylacetate:hexane as the eluant to give 18.7 g (92%) of t-butyl4-methyl-1H-benzimidazole-1-carboxylate as an oil.

Part B. t-butyl 4-(bromomethyl)-1H-benzimidazole-1-carboxylate (compoundXXa)

A mixture of t-butyl 4-methyl-1H-benzimidazole-1-carboxylate (11.6 g,0.05 mol), N-bromosuccinide (8.9 g, 0.05 mol) and benzoyl peroxide (0.25g) in carbon tetrachloride (100 mL) was stirred at reflux for 1 hour.The solution was cooled and filtered to remove succinimide by-productsand the solvent was removed. The crude product was chromatographed onsilica gel using ethyl acetate:hexane (1:20) as the initial eluant togive, as the first major product eluted from the column, 1.6 g oft-butyl 4-(dibromomethyl)-1H-benzimidazole-1-carboxylate;recrystallization from hexane gave 1.04 g of product, mp 101°-104° C.Anal. Calcd. for C₁₃ H₁₄ Br₂ N₂ O₂ : C, 40.03; H, 3.62; Br, 40.92; N,7.18. Found: C, 39.87; H, 3.83; Br, 41.18; N, 7.19.

Continued elution of the column gave 10.4 g of t-butyl4-(bromomethyl)-1H-benzimidazole-1-carboxylate. The compound wasrecrystallized from hexane to give 9.6 g of product, mp 87°-89° C. Anal.Calcd. for C₁₃ H₁₅ BrN₂ O₂ : C, 50.18; H, 4.86; Br, 25.68; N, 9.00.Found: C, 50.16; H, 5.04; Br, 25.71; N, 9.11.

Continued elution of the column gave 0.95 g of recovered t-butyl4-(bromomethyl)-1H-benzimidazole-1-carboxylate.

Following the procedure of Example 17 part B but substituting methyl4-methyl-1H-benzimidazole-1-carboxylate for t-butyl4-methyl-1H-benzimidazole-1-carboxylate there was obtained methyl4-(bromomethyl)-1H-benzimidazole-1-carboxylate (compound XXb).

Following the procedure of Example 17 part B but substituting1-acetyl-4-methyl-1H-benzimidazole for t-butyl4-methyl-1H-benzimidazole-1-carboxylate there was obtained1-acetyl-4-(bromomethyl)benzimidazole (compound XXc), mp 109°-112° C.Anal. Calcd. for C₁₀ H₁₀ BrN₂ O: C, 47.45; H, 3.58; Br, 31.58; N, 11.07.Found: C, 47.47; H, 3.82; Br, 29.17; N, 11.21.

EXAMPLE 18 5,6-Dihydro-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine(compound 6)

Part A. Diethyl{(1,1-dimethylethoxycarbonyl)-1H-benzimidazole-4-yl)methyl)-(dipropylamino)propanedioate(compound XXIa)

Potassium hydride (3.3 g of 40% oil suspension, washed with ether toremove oil, 0.03 mol) was added to a stirred solution of diethyl(dipropylamino)-malonate (10.2 g, 0.039 mol) in dry THF (100 mL). After5 minutes, t-butyl, 4-(bromomethyl)-1H-benzimidazole-1-carboxylate (6.22g, 0.02 mol) was added and the solution was refluxed for 6 hours. Thesolvent was removed under reduced pressure and the residual oil waspartitioned between ethyl acetate and water. After evaporation of theethyl acetate, the crude product was chromatographed on silica gel usingethyl acetate:hexane as the eluant to give 7.9 g of diethyl{((1,1-dimethylethoxycarbonyl)-1H-benzimidazole-4-yl)methyl}(dipropylamino)-propanedioateas an oil.

Part B. Ethyl α-(dipropylamino)-1H-benzimidazole-4-propanoate (compoundXXII)

A mixture of diethyl{((1,1-dimethylethoxycarbonyl)-1H-benzimidazole-4-yl)methyl}(dipropylamino)propanedioate (3.4 g, 6.9 mmol) was dissolved in ethanol (50 ml) andtreated with sodium ethoxide in ethanol (35 mL of 0.8 M, 4 equiv) andwater (1.0 mL) and the reaction was refluxed for 4 hours. The solutionwas then cooled, neutralized by addition of 15 mL of 2.2 N HCl inethanol, filtered to remove sodium chloride, and the solvent was removedunder reduced pressure. The product was partitioned between ethylacetate and water, and the ethyl acetate was removed, and the crudeproduct was chromatographed on silica gel using chloroform as theinitial eluant. Elution of the column with 5% methanol chloroform gave1.60 g of ethyl α-(dipropylamino)-1H-benzimidazole-4-propanoate. Theproduct was crystallized from ethyl acetate:hexane; mp 78°-80° C. Anal.Calcd. for C₁₈ H₂₇ N₃ O₂ : C, 68.11; H, 8.57; N, 13.24. Found: C, 68.41;H, 8.51; N, 13.22.

Part C β-(Dipropylamino)-1H-benzimidazole-4-propanol (compound XXIII)

Lithium aluminum hydride (250 mg, 6.6 mmol) was added at 0° C. to astirred solution of ethylα-(dipropylamino)-1H-benzimidazole-4-propanoate (1.5 g, 4.7 mmol) in dryTHF (50 mL), and the solution was allowed to warm to room temperature.TLC in 10% methanol:chloroform showed that the reaction was complete in15 minutes. Ethanol (5 mL) was added and the solvents were removed underreduced pressure. The residue was partitioned between ethyl acetate andwater. Evaporation of the ethyl acetate gave 1.3 g ofβ-(dipropylamino)-1H-benzimidazole-4-propanol which was used withoutfurther purification.

Part D 5,6-Dihydro-N,N-dipropyl-4H-imidazol(4,5,1-ij)quinolin-5-amine(compound 6)

Triphenylphosphine (625 mg, 2.4 mmol) was added to a stirred solution ofβ-(dipropylamino)-1H-benzimidazole-4-propanol (600 mg, 2.18 mmol) inmethylene chloride (12 mL). After solution was complete, carbontetrabromide (940 mg, 2.8 mmol) was added and the solution was stirredfor 30 minutes. Methylene chloride (20 mL) was added and the solutionwas extracted with 25 mL 1.0 N hydrochloric acid. The methylene chloridewas separated, reextracted with 10 mL 1.0 N HCl, and the combinedaqueous extracts were basified (20 mL of 4.0 N NaOH) and extracted withethyl acetate. After removing the ethyl acetate, the product waschromatographed on silica gel using chloroform as the initial eluant togive 380 mg of product. A sample was crystallized from hexane foranalysis; mp 95°-98° C. Anal. Calcd. for C₁₆ H₂₃ N₃ : C, 74.66; H, 9.01;N, 16.33. Found: C, 74.28; H, 9.25; N, 16.36.

EXAMPLE 195,6-Dihydro-N,N-dimethyl-4H-imidazo(4,5,1-ij)quinoline-5-amine (compound7)

Part A(Dimethylamino){((1,1-dimethylethoxycarbonyl)-1H-benzimidazole-4-yl)methyl}-propanedioicacid methyl benzyl diester

This compound was obtained by following the procedure of Example 18 partA, but substituting (dimethylamino)propanedioic acid methyl benzyldiester (compound VIi) for diethyl (dipropylamino)malonate.

Part B. Methyl α-(dimethylamino)-1H-benzimidazole-4-propanoate.

A mixture of(dimethylamino){((1,1-dimethylethoxycarbonyl)-1H-benzimidazole-4-yl)methyl}-propanedioicacid methyl benzyl diester (6.0 g) and 10% palladium charcoal (1 g) inethanol (150 mL) was hydrogenated until hydrogen uptake ceased. Thesolution was filtered and evaporated to give 4.1 g of methylα-(dimethylamino)-1H-benzimidazole-4-propanoate as an oil.

Part C. β-(Dimethylamino)-1H-benzimidazole-4-propanol

This compound was obtained by following the procedure of Example 18 partC, but substituting methylα-(dimethylamino)-1H-benzimidazole-4-propanoate for ethylα-(dipropylamino)-1H-benzimidazole-4-propanoate.

Part D. 5,6-Dihydro-N,N-dimethyl-4H-imidazo(4,5,1-ij)quinolin-5-amine

This compound was obtained by following the procedure of Example 18 partC but substituting β-(dimethylamino)-1H-benzimidazole-4-propanol forβ-(dipropylamino)-1H-benzimidazole-4-propanol.

The bulk of the product was converted to the hydrochloride salt, mp264°-265° C. from methanol:ether. Anal. Calcd. for C₁₂ H₁₅ N₃.2HCl: C,52.56; H, 6.25; Cl, 25.86; N, 15.33. Found: C, 52.44; H, 6.53; Cl,25.64; N, 15.18.

EXAMPLE 20 1-(5,6-Dihydro-4H-imidazo(4,5,1-ij)quinolin-5-yl)pyrrolidine(compound 8)

This compound was prepared by following the procedure of Example 19, butsubstituting (1-pyrrolidinyl)propanedioic acid methyl benzyl diester(compound VIk) for (dimethylamino)propanedioic acid methyl benzyldiester (compound VIi). The bulk of the product was converted to thedihydrochloride salt, mp 291°-294° C.

EXAMPLE 21 1-(5,6-Dihydro-4H-imidazo(4,5,1-ij)quinolin-5-yl)piperidine(compound 9)

This compound was prepared by following the procedure of Example 19, butsubstituting (1-piperidinyl)propanedioic acid methyl benzyl diester(compound VIm) for (dimethylamino)propanedioic acid methyl benzyldiester (compound VIi). The bulk of the product was converted to thedihydrochloride salt, mp 287°-290° C.

EXAMPLE 22 4-(5,6-Dihydro-4H-imidazo(4,5,1-ij)quinolin-5-yl)morpholine(compound 10)

This compound was prepared by following the procedure of Example 19, butsubstituting (4-morpholinyl)propanedioic acid methyl benzyl diester(compound VIn) for (dimethylamino)propanedioic acid methyl benzyldiester (compound VIi). The bulk of the product was converted to thedihydrochloride salt, mp 290°-292° C.

EXAMPLE 23 1-(5,6-Dihydro-4H-imidazo(4,5,1-ij)quinolin-5-yl)-imidazole(compound 11)

This compound was prepared by following the procedure of Example 19, butsubstituting (1-imidazolyl)propanedioic acid methyl benzyl diester(compound VIp) for (dimethylamino)propanedioic acid methyl benzyldiester (compound VIi). The bulk of the product was converted to themonohydrobromide salt, mp 239°-242° C.

EXAMPLE 241-(5,6-Dihydro-4H-imidazo(4,5,1-ij)quinolin-5-yl)-4-methylpiperazine(compound 12)

This compound was prepared by following the procedure of Example 19, butsubstituting (4-methyl-1-piperazinyl)propanedioic acid methyl benzyldiester (compound VIq) for (dimethylamino)propanedioic acid methylbenzyl diester (compound VIi).

EXAMPLE 25N-(1-Phenylethyl)-5,6-Dihydro-4H-imidazo(4,5,1-ij)quinolin-5-amine(compound 13)

This compound was prepared by following the procedure of Example 18, butsubstituting diethyl (1-phenylethylamino)malonate (compound VIg) fordiethyl (dipropylamino)malonate (compound VIb).

EXAMPLE 26 t-Butyl4-(bromomethyl)-5-methoxy-1H-benzimidazole-1-carboxylate

Part A. 3-Chloro-2-methyl-6-nitrobenzenamine

A suspension of 2,6-dichloro-3-nitrotoluene (6.0 g, 29 mmol) in 50%methanolic ammonia (60 mL) was stirred at 130° C. (340 lb pressure) for18 hours. The autoclave was cooled to -30° C., opened, and theprecipitate was filtered off and washed with methanol to give 4.14 g(76%) of 3-chloro-2-methyl-6-nitrobenzenamine.

Part B. 3-Methoxy-2-methyl-6nitrobenzenamine

Sodium methoxide in methanol (110 mL of 25% solution, 0.49 mol, 20equiv) was added to a stirred suspension of3-chloro-2-methyl-6-nitrobenzenamine (4.0 g, 23.5 mmol) in methanol (250mL) and the mixture was stirred at reflux for 18 hours. The solution wascooled, neutralized with methanolic hydrogen chloride, filtered toremove sodium chloride, and the solvent was removed under reducedpressure. The residual solid was partitioned between ethyl acetate andwater. Evaporation of the ethyl acetate gave 3.7 g (86%) of3-methoxy-2-methyl-6-nitrobenzenamine.

Part C. 4-Methoxy-3-methyl-1,2-benzenediamine

A mixture of 3-methoxy-2-methyl-4-nitrobenzenamine (3.5 g, 19.0 mmol)and 10% palladium on carbon (1.0 g) in absolute ethanol (150 mL) washydrogenated (50 lb initial hydrogen pressure) until hydrogen uptake wascomplete (30 minutes). The solution was filtered through celite and theethanol was removed to give 2.84 g (98%) of4-methoxy-3-methyl-1,2-benzenediamine.

Part D. 5-Methoxy-4-methyl-1H-benzimidazole

A mixture of 4-methoxy-3-methyl-1,2-benzenediamine (2.8 g, 18.4 mmol)and formic acid (30 mL) was heated at 60° C. for 30 minutes. The formicacid was removed under pressure and the product was partitioned betweenchloroform and water containing sufficient sodium hydroxide to basifythe solution. After evaporation of the solvent the crude product waschromatographed (methanol:chloroform) to give 2.55 g (84%) of5-methoxy-4-methyl-1H-benzimidazole.

Part E. t-Butyl 5-methoxy-4-methyl-1H-benzimidazole-1-carboxylate

A mixture of 5-methoxy-4-methyl-1H-benzimidazole (2.5 g, 15.4 mmol) anddi-t-butyl dicarbonate (4.2 g, 19.3 mmol) in dioxane (70 mL) was heatedat 100° C. for 1 hour. After evaporation the solvent, the residue waschromatographed on silica gel to give 3.75 g (93%) of t-butyl5-methoxy-4-methyl-1H-benzimidazole-1-carboxylate.

Part F. t-Butyl 4-(bromomethyl)-5-methoxy-1H-benzimidazole-1-carboxylate

A mixture of N-bromosuccinimide (2.66 g, 15.0 mmol), benzoyl peroxide(0.35 g) and t-butyl 5-methoxy-4-methyl-1H-benzimidazole-1-carboxylate(3.70 g, 14.1 mmol) in carbon tetrachloride (70 mL) was refluxed for 1hour. The solution was cooled, filtered to remove succinimideby-products, evaporated, dissolved in ethyl acetate and chromatographedon silica gel using ethyl acetate:hexane as the eluant to give 4.8 g ofproduct. This was crystallized from ethyl acetate:hexane to give 3.6 g(75%) of t-butyl4-(bromomethyl)-5-methoxy-1H-benzimidazole-1-carboxylate, mp 127°-129°C. Anal. Calcd. for C₁₄ H₁₇ BrN₂ O₃ : C, 49.28; H, 5.02; Br, 23.42; N,8.21. Found: C, 49.27; H, 4.98; Br, 26.81; N, 7.71.

EXAMPLE 275,6-Dihydro-7-methoxy-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine(compound 14)

The compound was prepared by following the procedure of Example 18, butsubstituting t-butyl4-(bromomethyl)-5-methoxy-1H-benzimidazole-1-carboxylate for t-butyl4-(bromomethyl)-1H-benzimidazole-1H-carboxylate. The product wascrystallized from pentane; mp 46°-49° C. Anal. Calcd. for C₁₇ H₂₅ N₃ O:C, 71.04; H, 8.77; N, 14.62. Found: C, 70.80; H, 8.89; N, 14.80.

The bulk of the product was converted to the dihydrochloride salt.

EXAMPLE 285,6-Dihydro-8-methoxy-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine(compound 15)

This compound was prepared by following the procedure of Example 18, butsubstituting t-butyl4-(bromomethyl)-6-methoxy-1H-benzimidazole-1-carboxylate for t-butyl4-(bromomethyl)-1H-benzimidazole-1-carboxylate.

EXAMPLE 295,6-Dihydro-9-methoxy-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine(compound 16)

This compound was prepared by following the procedure of Example 18, butsubstituting t-butyl4-(bromomethyl)-7-methoxy-1H-benzimidazole-1-carboxylate for t-butyl4-(bromomethyl)-1H-benzimidazole-1-carboxylate.

EXAMPLE 305,6-Dihydro-7-methoxy-N,N-dimethyl-4H-imidazo(4,5,1-ij)quinolin-5-amine(compound 17)

This compound was prepared by following the procedure of Example 18, butsubstituting t-butyl4-(bromomethyl)-5-methoxy-1H-benzimidazole-1-carboxylate for t-butyl4-(bromomethyl)-1H-benzimidazole-1-carboxylate and diethyl(dimethylamino)malonate for diethyl (dipropylamino)malonate.

EXAMPLE 317-Chloro-5,6-dihydro-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine(compound 18)

This compound was prepared by following the procedure of Example 18, butsubstituting t-butyl5-chloro-4-(bromomethyl)-1H-benzimidazole-1-carboxylate for t-butyl4-(bromomethyl)-1H-benzimidazole-1-carboxylate.

EXAMPLE 325-(Dipropylamino)-5,6-dihydro-4H-imidazo-(4,5,1-ij)quinolin-7-ol(compound 19)

5,6-Dihydro-7-methoxy-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine(1.0 g) was heated at 130° C. in 48% hydrobromic acid for 2 hours. Thesolution was cooled and was then evaporated under reduced pressure. Thesolid thus obtained was crystallized from methanol:ether; mp 270° C.

EXAMPLE 335,6-Dihydro-5-(dipropylamino)-4H-imidazo(4,5,1-ij)quinolin-8-ol(compound 20)

This componud was prepared by following the procedure of Example 32, butsubstituting5,6-dihydro-8-methoxy-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-aminefor5,6-dihydro-7-methoxy-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine.

EXAMPLE 345,6-Dihydro-5-(dipropylamino)-4H-imidazo(4,5,1-ij)quinolin-9-ol(compound 21)

This compound was prepared by following the procedure of Example 32, butsubstituting5,6-dihydro-9-methoxy-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-aminefor5,6-dihydro-7-methoxy-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine.

EXAMPLE 35 N-(3-quinolyl)formamide (compound XXV)

A solution of acetic formic anhydride was prepared by slowly adding95-97% formic acid (20.80 g, 17.05 mL, 0.45 mol) to acetic anhydride(40.84 g, 37.7 mL, 0.40 mol) at 0° C. The solution was stirred at roomtemperature for 2 hours, then added to a stirred solution of3-aminoquinoline (28.84 g, 0.20 mol) in dry tetrahydrofuran (300 mL).After 15 minutes, the solution was evaporated, methanol (50 mL) wasadded, and the solution stirred for an additional 30 minutes. Thesolution was then evaporated under reduced pressure and the residual oilwas triturated with ether. The resulting white solid was filtered togive 28.7 g (84%) of product, mp 157°-160° C. Anal. Calcd. for C₁₀ H₈ N₂O: C, 69.75; H, 4.68; N, 16.27. Found: C, 69.45; H, 4.78; N, 16.31.

EXAMPLE 36 N-(1-Formyl-1,2,3,4-tetrahydro- 3-quinolyl)formamide(compound XXVI)

A mixture of N-(3-quinolyl)formamide (30.0 g, 0.175 mol), platinum oxide(2.0 g) and acetic acid (300 mL) was hydrogenated (50 lb. initial H₂pressure) until 2 equivalents of H₂ were consumed (reaction time 3hours). The mixture was filtered through celite and the acetic acidremoved under pressure. It was dissolved in ethyl acetate and washedwith NaOH solution and water. Evaporation of the ethyl acetate gave 29.4g of crude material. This was dissolved in 200 mL THF and acetic formicanhydride (prepared from formic acid (27.2 g, 0.59 mol) and aceticanhydride (53.5 g, 0.52 mol) was added at 0° C. After 15 minutes, thesolution was allowed to warm to room temperature, and after anadditional 15 minutes, methanol (60 mL) was added. The solution wasevaporated and the resulting oil was partitioned between ethyl acetateand 4N sodium hydroxide solution. The sodium hydroxide solution wasrepeatedly extracted with ethyl acetate. The combined ethyl acetate wasevaporated, and the crude product was purified by chromatography onsilica gel using 2.5% methanol:chloroform as eluant to give 22.55 g(69%) of product. An analytical sample was crystallized frommethanol:ether (1:3); mp 125°-128° C. Anal. Calcd. for C₁₁ H₁₂ N₂ O₂ :C, 64.69; H, 5.92; N, 13.72. Found: C, 64.60; H, 5.97; N, 13.66.

EXAMPLE 37 N-(1-Formyl-6-bromo-1,2,3,4-tetrahydro-3-quinolyl)formamide(compound XXVII)

Bromine (10.2 g, 0.064 mol) was added to a stirred solution ofN-(1-formyl-1,2,3,4-tetrahydro-3-quinolyl)formamide (14.0 g, 0.065 mol)in acetic acid (70 mL) containing anhydrous sodium acetate (10.2 g, 0.12mol). The solution was stirred for 30 minutes and water (500 mL) wasadded. The precipitate was filtered off and air dried to give 15.8 g(86%) of N-(1-formyl-6-bromo-1,2,3,4-tetrahydro-3-quinolyl)formamide, mp174°-178° C. A sample was recrystallized from ethanol for analysis; mp178°-181° C.

EXAMPLE 38 6-Bromo-1,2,3,4-tetrahydro-8-nitro-3-quinolinamine (compound(XXIX)

A mixture of N-(1-formyl-6-bromo-1,2,3,4-tetrahydro-3-quinolyl)formamide(12.8 g, 45.2 mmol) and sodium nitrate (12.8 g, 150 mmol) intrifluoracetic acid (100 mL) was stirred at room temperature for 18hours. The bulk of the solvent was removed under reduced pressure andthe residue was partitioned between ethyl acetate and water. The ethylacetate was washed with sodium hydroxide and water, and the ethylacetate was removed to give 14.2 g ofN-(1-formyl-6-bromo-1,2,3,4-tetrahydro-8-nitro-3-quinolyl)formamide(compound XXVIII) as a solid. This was dissolved in ethanolic hydrogenchloride (100 mL of 4.0 N), the mixture was refluxed for 1 hour, ether(200 mL) was added, and the precipitate was filtered off, washed withether and dried to give 12.8 g (82% of6-bromo-1,2,3,4-tetrahydro-8-nitro-3-quinolinamine dihydrochloride,mp >300° C.

EXAMPLE 39 5,6-Dihydro-4H-imidazo(4,5,1-ij)quinolin-5-aminedihydrochloride (compound 22)

A mixture of 6-bromo-1,2,3,4-tetra-8-nitrohydro-3-quinolinaminedihydrochloride (10.69 g, 0.031 mol), and 10% palladium on carbon (1.0g) in absolute ethanol (175 mL) was hydrogenated (50 lb initial H₂pressure) until the H₂ uptake had ceased (reaction time 1.5 hours). Themixture was filtered through celite and the solvent removed underreduced pressure. The residual foam was partitioned between ethylacetate and 1 N sodium hydroxide solution. Evaporation of the ethylacetate gave 5.41 g of 3,8-diamino-1,2,3,4-tetrahydroquinoline (compoundXXX) as a brown oil.

This oil was dissolved in formic acid (60 mL) and stirred at 55° C. for5 hours. The formic acid was then removed under high vacuum. Theresulting oil was partitioned between ethyl acetate (400 mL) and 4 Nsodium hydroxide (60 mL). The aqueous phase was extracted 5 times withethyl acetate and the combined ethyl acetate extracts were washed withwater 2×25 mL). The ethyl acetate was evaporated to give 5.5 g ofmaterial, a mixture of the desired product (80% and its N-formylderivative (20%). The crude product was dissolved in methanolic HCl (150mL) to hydrolyze the N-formyl compound. After 1.5 hours at roomtemperature, the precipitate which formed was filtered and washed withmethanol:ether (1:3) to give 6.33 g (82%) of5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-5-amine dihydrochloride,mp >300° C. Anal. Calcd. for C₁₀ H₁₁ N₃.2HCl: C, 48.80; H, 5.32; Cl,28.81 ; N, 17.07. Found: C, 48.68; H, 5.44; Cl, 28.60; N, 16.92.

EXAMPLE 40 5,6-Dihydro-N-propyl-4H-imidazo(4,5,1-ij)quinoline-5-amine(compound 23)

Propionaldehyde (11.0 g, 0.19 mol) and sodium cyanoborohydride (0.85 g,0.014 mol) were added at 0° C. to a stirred solution of5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-5-amine dihydrochloride (3.0 g,0.012 ml) in methanol (250 mL). After 20 minutes, methanolic ammonia (10mL) was added and the solution was concentrated to an oil andpartitioned between ethyl acetate and sodium hydroxide solution. Theethyl acetate phase was washed with water, evaporated, dissolved inchloroform and chromatographed on silica gel using 5%methanol:chloroform as eluant to get, as the first product eluted fromthe column, 0.9 g (32%) of5,6-dihydro-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinoline-5-amine.

Continued elution of the column gave 1.65 g (65%) of the monopropylaminederivative. This was dissolved in methanol and ethereal HCl and etheradded. The precipitate was filtered off and recrystallized twice frommethanol:ether to give 1.32 g of5,6-dihydro-N-propyl-4H-imidazo(4,5,1-ij)quinoline-5-aminesesquihydrochloride, mp 294°-297° C. (dec). Anal. Calcd. for C₁₃ H₁₇N₃.1.5HCl: C, 57.83; H, 6.91; Cl, 19.70; N, 15.56. Found: C, 57.84; H,7.04; Cl, 19.46; N, 15.26.

EXAMPLE 415,6-Dihydro-8-methyl-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine(Compound 24)

This compound was prepared by following the procedure of Example 40, butsubstituting 5,6-dihydro-8-methyl-4H-imidazo(4,5,1-ij)quinolin-5-aminedihydrochloride for 5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-5-aminedihydrochloride. The compound was crystallized from hexane; mp 91°-94°C. Anal. Calcd. for C₁₇ H₂₅ N₃ O: C, 75.23; H, 9.28; N, 15.48. Found:C75.08; H, 8.88; N, 15.67.

EXAMPLE 425,6-Dihydro-2-methyl-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine(Compound 25)

t-Butyl (8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate (2.72 g) wastreated with acetic anhydride (1.16 g) in THF (150 mL) for 2.5 hours.The reaction was evaporated and the crude product was dissolved inmethanolic hydrogen chloride. After 5 hours, the solvent was removed togive 3.1 g of 5,6-dihydro-2-methyl-4H-imidazo(4,5,1-ij)quinolin-5-aminedihydrochloride.

This was converted to5,6-dihydro-2-methyl-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amineusing the procedure of Example 40. The product was converted to thedihydrochloride salt, mp 202°-205° C. Anal. Calcd. for C₁₃ H₁₇ N₃.2HCl:C, 59.28; H, 7.91; Cl 20.59; N, 12.20. Found: C, 58.51; H, 8.02; Cl,21.90; N, 11.41.

EXAMPLE 43 t-Butyl(6-bromo-1,2,3,4-tetrahydro-8-nitro-3-quinolinyl)carbamate (compoundXXXI)

A mixture of 6-bromo-1,2,3,4-tetrahydro-8-nitro-3-quinolinamine (3.45 g,0.01 mol), di t-butyl dicarbonate (3.0 g, 0.014 mol) and triethylamine(2.0 g, 0.02 mol) in DMF (50 mL) was stirred at room temperature for 1hour. Water (7 mL) was slowly added to the stirred solution. Theprecipitate was filtered off and washed with water and air dried to give3.7 g of bright orange solid, mp 193°-195° C. Anal. Calcd. for C₁₄ H₁₈BrN₃ O₄ : C, 45.17; H, 4.87; Br, 21.47; N, 11.29. Found: C, 45.25; H,4.97; Br, 21.34; N, 11.38.

EXAMPLE 44 t-Butyl(1,2,5,6-tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)carbamate(compound XXXIII)

Part A. t-butyl (8-amino-1,2,3,4-tetrahydro-3-quinolinyl)carbamate

A mixture of t-butyl(6-bromo-1,2,3,4-tetrahydro-8-nitro-3-quinolinyl)-carbamate (3.72 g,0.01 mol), absolute ethanol (150 mL) and 10% palladium on carbon (0.60g) was hydrogenated (50 lb hydrogen pressure) for 18 hours. The mixturewas filtered through celite and the solvent removed. The residual foamwas partitioned between ethyl acetate and 1 N sodium hydroxide, and theethyl acetate phase was evaporated under reduced pressure to give 2.72 gof t-butyl (8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate (compoundXXXII) as an oil.

Part B. t-Butyl(1,2,5,6-tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)carbamate(compound XXXIII)

t-Butyl (8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate (2.70 g) wasdissolved in THF (100 mL) and stirred while a solution of phosgene inTHF (20.7 mL of 0.40 M, 0.093 mol) was added. After 5 minutes,triethylamine (2.08 g, 0.020 mol) was added and the solution stirred foran additional 10 minutes. The THF was removed under reduced pressure andthe material was partitioned between chloroform (250 mL) and water (20mL). The chloroform was washed with 4N sodium hydroxide (5 mL) andevaporated. The crude material was combined with that of an earlierreaction (0.002 mol scale) and purified by chromatography on silica gelin 1% methanol:chloroform to give 2.28 g of product. Crystallizationfrom methanol:ether (1:1) gave 1.60 g (54%) white solid, mp 235°-236° C.Anal. Calcd. for C₁₅ H₁₉ N₃ O₃ : C, 62.26; H, 6.62; N, 14.52. Found: C,61.65 ; H, 6.94; N, 14.23.

EXAMPLE 45 5-Amino-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one(compound 26)

t-Butyl(1,2,5,6-tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)carbamate(1.65 g, 0.057 mol) was dissolved in methanol HCl (85 mL) and stirred atroom temperature for 1 hour. The solvent was removed under reducedpressure to give 1.29 g of crude product. An analytical sample wasrecrystallized from methanol and ether to give a pink solid, mp >300° C.Anal. Calcd. for C₁₀ H₁₁ N₃ O.HCl.1/2H₂ O: C, 51.58; H, 5.58; Cl, 15.11;N, 17.90. Found: C, 51.04; H, 5.47; Cl, 15.10; N, 17.86.

EXAMPLE 465-(Dimethylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-onehydrochloride (compound 27)

5-Amino-5,6-dihydro-4H-imidazo-4,5,1-ij)quinolin-2(1H)-one (0.73 g, 3.2mmol) was dissolved in 1N sodium hydroxide solution (3.2 mL). To thiswas added absolute ethanol (100 mL), 37% formaldehyde solution (1.3 mL),10% palladium on carbon (0.65 g), and the mixture was hydrogenated (50lb. initial H₂ pressure) until H₂ uptake ceased (reaction time 5 hours).The mixture was filtered through celite and the solvent removed underreduced pressure to yield a clear oil. The crude material was combinedwith that of a previous reaction (2.5 mmol), dissolved in chloroform andgravity filtered to remove paraformaldehyde. The compound was purifiedby chromatographing on silica gel in 10% methanol:chloroform to give0.88 g (71%) of5-(dimethylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one anoil.

The bulk of the product was converted to the hydrochloride salt, mp220°-223° C. Anal. Calcd. for C₁₂ H₁₅ N₃ O.HCl.1/2H₂ O: C, 54.85; H,6.52; Cl, 13.49; N, 15.99. Found: C, 54.97; H, 6.33; Cl, 13.08; N,15.55.

EXAMPLE 475-(Propylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one(compound 28)

Sodium cyanoborohydride (0.17 g) was added in small portions over a5-hour period to a stirred solution of 1.90 g (8.4 mmol)5-amino-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one, 0.85 mLsodium methoxide and 1.5 g propionaldehyde in methanol (175 mL).Methanolic ammonia solution was added, and after 30 minutes, the solventwas evaporated. The residual oil was partitioned between ethyl acetateand water and the crude product obtained by evaporating the ethylacetate was dissolved in chloroform and chromatographed on silica geleluting with 2.5% methanol:chloroform to give 1.24 g (64% yield) of5,6-dihydro-5-(propylamino)-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one.

The bulk of the product was converted to the hydrochloride salt,mp >300° C. from methanol:ether. Anal. Calcd. for C₁₃ H₁₇ N₃ O.HCl: C,58.31; H, 6.77; Cl, 13.24; N, 15.69. Found: C, 58.16; H, 6.92; Cl,13.17; N, 15.18.

EXAMPLE 485-(Dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one(compound 29)

Propionaldehyde (12.7 g, 0.21 mol) and sodium cyanoborohydride (2.22 g,0.035 mol) were added at 0° C. to a stirred solution of5-amino-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one (2.70 g,0.012 mol) and sodium methoxide (1 mL of 3.8 M) in methanol (250 mL).The solution was allowed to warm to room temperature and, after 1 hour,methanolic ammonia (10 mL) was added. The solution was stirred anadditional 30 minutes and the solvent removed under reduced pressure.The mixture was dissolved in EtOAc (500 mL), washed with 4N NaOH (15 mL)and H₂ O (2×10 mL) and evaporated. The crude product was dissolved inchloroform:methanol (2:1) and chromatographed on silica gel eluting withchloroform. The solid obtained was triturated with ether:hexane (1:1, 40mL) and filtered to give 2.12 g (65%) of product, mp 155°-157° C. Theanalytical sample was recrystallized from ethyl acetate:hexane; mp155°-158° C. Anal. Calcd. for C₁₆ H₂₃ N₃ O: C, 70.29; H, 8.48; N, 15.37.Found: C, 70.36; H, 8.78; N, 15.30.

The bulk of the product was converted to the hydrochloride salt, mp221°-224° C. (dec). Anal. Calcd. for C₁₆ H₂₃ N₃ O.HCl: C, 62.02; H,7.81; Cl, 11.44; N, 13.56. Found: C, 61.88; H, 7.79; Cl, 11.50; N,13.48.

EXAMPLE 49 (-)5-(Dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one((-) compound 29)

Part A. (+) and (-) t-ButoxycarbonylN-(1,2,5,6-tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)-L-phenylalaninamide

A mixture of t-butoxycarbonyl-L-phenylalanine (2.9 g, 11 mmol),5-amino-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one hydrochloride(2.25 g, 10 mmol), 1-hydroxybenzotriazole (1.65 g, 11 mmol),triethylamine (1.1 g, 11 mmol) and dicyclohexylcarbodiimide (3.09 g, 15mmol) in dimethylformamide (50 mL) was stirred at room temperature for 2hours. The solution was filtered to remove dicyclohexylurea, evaporated,and chromatographed to give, as the first product eluted from thecolumn, 1.8 g of (+) t-butoxycarbonylN-(1,2,5,6-tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)-L-phenylalaninamide.This was crystallized from methanol; mp 215°-217° C.; (α)_(D) ^(MeOH)+26°. Anal. Calcd. for C₂₄ H₂₈ N₄ O₄ : C, 66.03; H, 6.47; N, 12.84.Found: C, 66.01; H, 6.54; N, 13.01.

Continued elution of the column gave 1.9 g of (-) t-butoxycarbonylN-(1,2,5,6-tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)-L-phenylalaninamide.

Part B. (-) 5-amino-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one

(-) t-ButoxycarbonylN-(1,2,5,6-tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)-L-phenylalaninamide(1.8 g) was stirred in ethanolic hydrogen chloride (50 mL of 4.0 N) for1 hour. The solvent was removed and the residual oil was partitionedbetween chloroform and sodium hydroxide solution. Evaporation of thechloroform gave 1.4 g of (-)N-(1,2,5,6-tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)phenylalaninamide.This was dissolved in acetonitrile:THF (30 mL of 1:1) and phenylisothiocycanate (675 mg, 5 mmol) was added. After 1 hour, the solventswere removed and the residual oil was chromatographed on silica gelusing chloroform as the initial eluant. Elution of the column with 5%methanol:chloroform gave 1.8 g of (-)N-((phenylamino)thiocarbonyl)-N-(1,2,5,6-tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)phenylalaninamide.This was dissolved in trifluoroacetic acid (25 mL). After 1 hour thesolvent was removed and the residue was dissolved in methanol (5 mL).Ether (50 mL) was added, the solution was cooled to - 10° C., and theprecipitate was filtered off, washed with ether, and air dried to give1.2 g of (-) 5-amino-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-onetrifluoroacetate, mp 247° C. (dec). (α)_(D) ^(MeOH) -18°. Anal. Calcd.for C₁₀ H₁₁ N₃ O.C₂ HF₃ O₂ : C, 47.53; H, 3.99; F, 18.80; N, 13.97.Found: C, 47.31; H, 4.26; F, 17.37; N, 13.48.

Part C. (-)5-(Dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one

This was prepared following the procedure of Example 47, but using (-)5-amino-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-onetrifluoroacetate in place of5amino-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one. Thehydrochloride salt of the product crystallized from methanol:ether as ahemihydrate (2.89% water content) with an indefinite melting point;(α)_(D) ^(MeOH) -16.5°. Anal. Calcd. for C₁₆ H₂₃ N₃ O.HCl.1/2H₂ O: C,62.02; H, 7.81; N, 13.56; Cl, 11.44. Found: C, 61.88; H, 7.79; N, 13.48;Cl, 11.50. The compound was also converted to the hydrobromide saltwhich was obtained as a monohydrate, mp 190°-192° C. frommethanol/ether.

EXAMPLE 50 (+)5-(Dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-onehydrochloride

This was prepared from (+) t-butoxycarbonylN-(1,2,5,6-tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)-L-phenylalaninamideusing the procedures described in Example 49, parts B and C. Thehydrochloride salt of the product crystallized from methanol:ether as ahydrate (0.99% water content) with an indefinite melting point; (α)_(D)^(MeOH) +16.5°. Anal. Calcd. for C₁₆ H₂₃ N₃ O.HCl.1/4H₂ O: C, 61.13; H,8.01; Cl, 11.28; N, 13.37. Found: C, 61.17; H, 8.08; Cl, 11.12; N,13.35.

EXAMPLE 515-(Dipropylamino)-5,6-dihydro-1-methyl-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one(compound 30)

Potassium hydride (0.28 g of a 35% by wt. mineral oil dispersion, washedwith ether to remove oil, 2.7 mmol) in dry THF was added to a stirredsolution of5-dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one(0.60 g, 2.2 mmol) in dry THF (25 mL). Methyl iodide (0.31 g, 2.2 mmol)in dry THF was then added. After stirred at room temperature for 18hours, methanol was slowly added to the solution. The solvent was thenremoved under reduced pressure and the material dissolved inmethanol:chloroform (1:1) and chromatographed on silica gel usingchloroform as eluant to give 0.50 g (79% yield) of a yellow solid. Theproduct was recrystallized twice from hexane to give 0.28 g (44%) of5-(dipropylamino)-5,6-dihydro-1-methyl-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one,mp 83°-85° C. Anal. Calcd. for C₁₇ H₂₅ N₃ O: C, 71.04; H, 8.77; N,14.62. Found: C, 71.25; H, 8.91; N, 14.74.

EXAMPLE 525-(Dimethylamino)-5,6-dihydro-1-methyl-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one(compound 31)

This compound was prepared by following the procedure of Example 51, butsubstituting5-(dimethylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one for5-(dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one.

The product was converted to the hydrochloride salt which wascrystallized from methanol:ether; mp 268°-271° C. Anal. Calcd. for C₁₃H₁₇ N₃ O.HCl: C, 58.31; H, 6.77; Cl, 13.24; N, 15.69, Found: C, 58.40;H, 6.92; Cl, 13.05; N, 15.33.

EXAMPLE 535-(Dimethylamino)-5,6-dihydro-8-methyl-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one(compound 32)

This compound was prepared by following the procedure of Example 46, butsubstituting5-amino-5,6-dihydro-6-methyl-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one for5-amino-5,6-dihydro-4H-imidazo-(4,5,1-ij)quinolin-2(1H)-one.

The product was converted to the hydrochloride salt which wascrystallized from methanol:ether; mp 281°-284° C. Anal. Calcd. for C₁₃H₁₇ N₃ O.HCl: C, 58.31; H, 6.77; Cl, 13.24; N, 15.69. Found: C, 58.00;H. 7.03; Cl, 12.94; N, 15.44.

EXAMPLE 546-Bromo-1,2,3,4-tetrahydro-8-nitro-N,N-dipropyl-3-quinolinamine(compound XXXIa)

A mixture of 6-bromo-1,2,3,4-tetrahydro-8-nitro-3-quinolinaminedihydrochloride (11.5 g, 0.033 mol), idopropane (21 g, 0.12 mol) andanhydrous sodium carbonate (20 g, 0.19 mol) in dimethylformamide (100mL) was stirred at 100° C. for 5 hours. The solution was thenevaporated, partitioned between ethyl acetate and water, and the ethylacetate was evaporated to give a red oil. This was chromatographed onsilica gel to give 8.2 g of6-bromo-1,2,3,4-tetrahydro-8-nitro-N,N-dipropyl-3-quinolinamine. Theproduct was crystallized from ethyl acetate:hexane to give 7.6 g ofproduct, mp 79°-81° C. Anal. Calcd. for C₁₅ H₂₂ BrN₃ O₂ : C, 50.57; H,6.23; Br, 22.43; N, 11.79. Found: C, 50.59; H, 6.27; Br, 22.53; N,11.69.

Continued elution of the column afforded 1.5 g of6-bromo-1,2,3,4-tetrahydro-8-nitro-N-propyl-3-quinolinamine as an oil.

EXAMPLE 556-Bromo-1,2,3,4-tetrahydro-N,N-dimethyl-8-nitro-3-quinolinamine(compound XXXIb)

A mixture of 6-bromo-1,2,3,4-tetrahydro-8-nitro-3-quinolinamine (1.5 g,5.5 mol), 37% aqueous formaldehyde (1.8 mL) and formic acid (10 mL) washeated at 100° C. for 1 hour. The solution was then evaporated,partitioned between ethyl acetate (200 mL) and 4 N sodium hydroxidesolution (10 mL), and the ethyl acetate was evaporated to give a redoil. This was chromatographed on silica gel to give 1.58 g of6-bromo-1,2,3,4-tetrahydro-8-nitro-N,N-dipropyl-3-quinolinamine. Theproduct was crystallized from ethyl acetate:hexane; mp 88°-91° C. Anal.Calcd. for C₁₁ H₁₄ BrN₃ O₂ : C, 44.01; H, 4.70; Br, 26.62; N, 14.00.Found: C, 44.04; H, 4.89; Br, 26.62; N, 13.97.

EXAMPLE 565-(Dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-thione(Compound 33)

Part A. 1,2,3,4-Tetrahydro-N³,N³ -dipropyl-3,8-quinolinediamine(compound XXXVb)

A mixture of6-bromo-1,2,3,4-tetrahydro-8-nitro-N,N-dipropyl-3-quinolinamine (2.7 g)and 10% palladium charcoal (0.5 g) in ethanol (150 mL) was hydrogenatedfor 18 hours. The solution was filtered and the ethanol evaporated togive 1.9 g of 1,2,3,4-tetrahydro-N³,N³ -dipropyl-3,8-quinolinediamine asan oil.

Part B.5-(Dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-thione

Di (2-pyridyl)thiocarbonate (1.6 g, 7.2 mmol) was added to a stirredsolution of 1,2,3,4-tetrahydro-N³,N³ -dipropyl-3,8-quinolinediamine (1.6g, 6.7 mmol) in THF (50 mL). The solution was stirred for 1 hour,evaporated, and partitioned between chloroform and water. The chloroformphase was evaporated and chromatographed on silica gel using ethylacetate:hexane (1:9) as the initial eluant to give 1.6 g of product.Crystallization from cyclohexane gave 1.3 g (67% of5-(dipropylamino)-5,6-hydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-thione,mp 150°-151° C. Anal. Calcd. for C₁₆ H₂₃ N₃ S: C, 66.39; H, 8.01; N,14.52; S, 11.08. Found: C, 66.50; H, 8.18; N, 14.56; S, 11.02.

EXAMPLE 575,6-Dihydro-2-methylthio-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine(compound 34)

This compound was prepared using the procedure of Example 51, butsubstituting5-(dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-thionefor5-(dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one.The product was crystallized from pentane; mp 49°-52° C. Anal. Calcd.for C₁₇ H₂₅ N₃ S: C, 67.28; H, 8.30; N, 13.85; S, 10.57. Found: C,67.57; H, 8.27; N, 14.00; S, 10.44.

EXAMPLE 58 5,6-Dihydro-N⁵,N⁵-dipropyl-4H-imidazo(4,5,1-ij)quinoline-2,5-diamine (compound 35)

This compound was prepared using the procedure of Example 56 part B, butsubstituting cyanogen bromide for di (2-pyridyl)thiocarbonate. Theproduct was purified by chromatography and tritutated with ether; mp160°-170° C. Anal. Calcd. for C₁₆ H₂₄ N₄ : C, 70.55; H, 8.88; N, 20.57.Found: C, 68.96; H, 9.03; N, 20.57.

EXAMPLE 59 5,6-Dihydro-N² -methyl-N⁵,N⁵-dipropyl-4H-imidazo(4,5,1-ij)quinoline-2,5diamine (compound 36)

This compound was prepared using the procedure of Example 51, butsubstituting 5,6-dihydro-N⁵,N⁵-dipropyl-4H-imidazo(4,5,1-ij)quinoline-2,5-diamine for5-(dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one.The product was separated by chromatography from the accompanying5,6-dihydro-1-methyl-N⁵,N⁵-dipropyl-4H-imidazo(4,51-ij)quinoline-2,5-diamine.

EXAMPLE 60 5-(Dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2-yl)cyanamide (compound 37)

This compound was prepared using the procedure of Example 56 part B, butsubstituting diphenyl cyanocarbonimidate for di(2-pyridyl)thiocarbonate.

EXAMPLE 61 5,6-Dihydro-N,N-dipropyl-1H,4H-thiadiazolo(4,3,2-ij)quinoline-5-amine 2,2-dioxide (compound 38)

This compound was prepared using the procedure of Example 56 part B, butsubstituting sulfamide for di (2-pyridyl)thiocabonate and carrying thereaction out at 150° C. in absence of solvent.

EXAMPLE 621,2,6,7-Tetrahydro-6-(dipropylamino)-3H,5H-pyrido(1,2,3-de)quinoxalin-3-one(compound 39)

This compound was prepared using the procedure of Example 56, butsubstituting ethyl bromoacetate for di (2-pyridyl)thiocarbonate andcarrying the reaction out at the reflux temperature. The crude productwas chromatographed to give, as the major product and first compoundeluted from the column,1,2,6,7-tetrahydro-6-(dipropylamino)-3H,5H-pyrido(1,2,3-de)quinoxalin-3-one.The product was crystallized from ethyl acetate:hexane; mp 97°-99° C.Anal Calcd. for C₁₇ H₂₅ N₃ O: C, 71.04; H, 8.77; N, 14.62. Found: C.71.20; H, 8.90; N, 14.85.

Continued elution of the column have a small amount of1,2,6,7-tetrahydro-6-(dipropylamino)-3H,5H-pyrido(1,2,3-de)quinoxalin-2-one.

EXAMPLE 631,2,6,7-Tetrahydro-6-(dipropylamino)-3H,5H-pyrido(1,2,3-de)quinoxalin-2-one(compound 40)

This compound was prepared using the procedure of Example 56, butsubstituting chloroacetic anhydride for di (2-pyridyl)thiocarbonate. Theinitially formed N⁸ -(chloroacetyl)-1,2,3,4-tetrahydro-N³,N³-dipropyl-3,8-quinolinediamine was heated at 150° C. in DMF to effectcyclization to 1,2,6,7-tetrahydro-6-(dipropylamino)-3H,5H-pyrido(1,2,3-de)quinoxalin-2-one which was thereby obtained as thehydrochloride salt which was crystallized from methanol:ether; mp250°-255° C. (dec). Anal. Calcd. for C₁₇ H₂₅ N₃ O:HCl: C, 63.04; H,8.09; Cl, 10.95; N, 12.98. Found: C, 62.39; H, 8.34; Cl, 10.85; N,12.84.

EXAMPLE 646,7-Dihydro-6-(dipropylamino)-3H,5H-pyrido(1,2,3-de)quinoxalin-3-one(compound 41)

This compound was prepared using the procedure of Example 56, butsubstituting butyl glyoxylate for di (2-pyridyl)thiocarbonate andcarrying the reaction out at the reflux temperature.

The bulk of the product was converted to the p-toluenesulfonate salt, mp188°-190° C. from methanol:ether.

EXAMPLE 656,7-Dihydro-6-(dipropylamino)-1H,5H-pyrido(1,2,3-de)quinoxalin-2,3-dione(compound 42)

This compound was prepared using the procedure of Example 56, butsubstituting ethyl oxalyl chloride for di (2-pyridyl)thiocarbonate andcarrying the reaction out at the reflux temperature. The product wascrystallized from ethyl acetate:hexane; mp 166°-168° C. Anal. Calcd. forC₁₇ H₂₃ N₃ O₂ : C, 67.75; H, 7.69; N, 13.94. Found: C, 67.66; H, 7.96;N, 13.80.

The bulk of the product was converted to the hydrochloride salt whichwas crystallized from methanol:ether; mp 250°-255° C. (dec).

EXAMPLE 665-(Dimethylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-thione(compound 43)

Part A. 1,2,3,4-Tetrahydro-N³,N³ -dimethyl-3,8-quinolinediamine(compound XXXVb)

A mixture of6-bromo-1,2,4-tetrahydro-8-nitro-N,N-dimethyl-3-quinolinamine (1.15 g,3.8 mmol) and 10% palladium charcoal (0.5 g) in ethanol (150 mL) washydrogenated for 18 hours. The solution was filtered and the ethanolevaporated to give 0.73 g of 1,2,3,4-tetrahydro-N³,N³-dimethyl-3,8-quinolinedimaine as an oil.

Part B.5-(Dimethylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-thione

Di (2-pyridyl)thiocarbonate (0.92 g, 4.0 mmol) was added to a stirredsolution of 1,2,3,4-tetrahydro-N³, N³ -dimethyl-3,8-quinolinedimaine(0.73 g, 3.8 mmol) in THF (50 mL). The solution was stirred for 1 hour,evaporated, and partitioned between chloroform and water. The chloroformphase was evaporated and chromatographed on silica gel using ethylacetate:hexane (1:9) as the initial eluant to give 0.68 g of product.Crystallization from cyclohexane gave 0.60 g of5-(dimethylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-thione,mp 203°-205° C. Anal. Calcd. for C₁₂ H₁₅ N₃ S: C, 61.77; H, 6.48; N,18.01; S, 13.74. Found: C, 61.77; H, 6.53; N, 17.73; S.

EXAMPLE 67 Alternate synthesis of 1,2,3,4-Tetrahydro-N³,N³-dimethyl-3,8-quinolinediamine (compound XXXVb)

Part A. Diethyl (formylamino)(2-nitrophenyl)methyl)propanedioate

Diethyl (formylamino)malonate (20.3 g, 0.1 mol) was added to a stirredsolution of sodium ethoxide (250 mL of 0.4M). 2-Nitrobenzylchloride(17.2 g, 0.1 mol) was added, the mixture was refluxed for 2 hours andthe solvent was then removed under reduced pressure. The material waspartitioned between ethyl acetate and water, the ethyl acetate wasseparated and evaporated to give 40.3 g of crude product. The compoundwas crystallized from ethyl acetate:hexane to give 25.5 g of diethyl(formylamino)(2-nitrophenyl)methyl)propanedioate; mp 129°-132° C.

Part B. Ethyl3-(formylamino)-1,2,3,4-tetrahydro-2-oxo-3-quinolinecarboxylate

A mixture of diethyl (formylamino)(2-nitrophenyl)methyl)propanedioate(8.54 g, 0.025 mol) and 10% palladium on carbon (2.0 g) in absoluteethanol (200 mL) was hydrogenated (50 lb initial H₂ pressure) untilhydrogen uptake ceased. The mixture was filtered through celite andrefluxed for 2 hours to achieve cyclization. The solvent was removedunder reduced pressure to give 6.6 g of product which was crystallizedfrom methanol to give 5.0 g of white crystals. mp 187°-190° C. Anal.Calcd. for C₁₃ H₁₄ N₂ O₄ : C, 59.53; H, 5.38; N, 10.68. Found: C, 59.77;H, 5.36; N, 10.75.

Part C. 3-(Formylamino)-3,4-dihydro-2(1H)quinolinone

Sodium hydroxide (50 mL of 4.0N, 0.20 mol) was added to a stirredsolution of ethyl3-(formylamino)-1,2,4,-tetrahydro-2-oxo-3-quinolinecarboxylate (11.3 g,0.043 mol) in methanol (250 mL). After 30 minutes, a white precipitateappeared and, after 45 minutes water (50 mL) was added to the reaction.After refluxing overnight, hydrochloric acid (50 mL of 4.0N, 0.20 mol)was added and the solvents were removed under reduced pressure. Theresidual solid was refluxed in ethanol (200 mL) for 1 hour, filtered toremove salt, and cooled to afford 6.8 g of product, mp 197°-200° C.Anal. Calcd. for C₁₀ H₁₀ N₂ O₂ : C, 63.15; H, 5.30; N, 14.73. Found: C,63.03; H, 5.37; N, 14.71.

Part D. 3-(Formylamino)-6-bromo-3,4-dihydro-8-nitro-2(1H)quinolinone

Bromine (16.0 g, 0.1 mol) was added to a stirred solution of3-(formylamino)-3,4-dihydro-2(1H)quinolinone (19.0 g, 0.1 mol) andanhydrous sodium acetate (12.7 g, 0.2 mol) in acetic acid (500 mL).After 1 hour, water (1.5 L) was added and the precipitate was filteredoff and air dried to give 17.8 g of3-(formylamino)-6-bromo-3,4-dihydro-2(1H)quinolinone, mp 275°-282° C.(dec). This was dissolved in trifluoracetic acid (300 mL) and sodiumnitrate (9.0 g) was added to the stirred solution. After 1 hour, waterwas added and the precipitate was filtered off and air dried to give18.2 g of 3-(formylamino)-6-bromo-3,4-dihydro-8-nitro-2(1H)quinolinone,mp 232°-235° C.

Part E. 3-(Amino)-6-bromo-3,4-dihydro-8-nitro-2(1H)quinolinone

This compound was prepared using the procedure of Example 9 part A, butsubstituting 3-(formylamino)-6-bromo-3,4-dihydro-8-nitro-2(1H)quinolinone forN-(2,3,6,7-tetrahydro-3-oxo-1H,5H-benzo(ij)quinolizin-2-yl)-formamide.

Part F. 3-(Dimethylamino)-6-bromo-3,4-dihydro-8-nitro-2(1H)quinolinone

This compound was prepared using the procedure of Example 55, butsubstituting3-(formylamino)-6-bromo-3,4-dihydro-8-nitro-2(1H)quinolinone for6-bromo-1,2,3,4-tetrahydro-8-nitro-3-quinolinamine. The product wascrystallized from ethyl acetate; mp 162°-165° C.

Part G. 3,8-Diamino-3,4-dihydro-N³,N³ -dimethyl-2(1H)quinolinone

This compound was prepared using the procedure of Example 56 part A, butsubstituting3-(dimethylamino)-6-bromo-3,4-dihydro-8-nitro-2(1H)quinolinone for6-bromo-1,2,3,4-tetrahydro-8-nitro-N,N-dipropyl-3-quinolinamine.

Part H. 1,2,3,4-Tetrahydro-N³,N³ -dimethyl-3,8-quinolinediamine

This compound was prepared using the procedure of Example 14, butsubstituting 3,8-diamino-3,4-dihydro-N³,N³ -dimethyl-2(1H)quinolinoneforN-(2,3,6,7-tetrahydro-3-oxo-1H,5H-benzo(ij)quinolizin-2-yl)propanamide.

EXAMPLE 685,6-Dihydro-N,N-dimethyl-2-methylthio-4H)imidazo(4,5,1-ij)quinoline-5-amine(compound 44)

This compound was prepared using the procedure of Example 51, butsubstituting5-(dimethylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-thionefor5-(dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one.The product was crystallized from ethyl acetate:hexane; mo 84°-86° C.Anal. Calcd. for C₁₃ H₁₇ N₃ S: C, 63.12; H, 6.93; N, 16.99; S, 12.96.Found: C, 63,08; H, 7.02; N, 16.97; S, 12.82.

EXAMPLE 69 5,6-Dihydro-N⁵, N⁵ -dimethyl-4H-imidazo)4,5,1ij)quinoline-2,5-diamine (compound 45)

This compound was prepared using the procedure of Example 66, butsubstituting cyanogen bromide for di (2-pyridyl)thiocarbonate.

EXAMPLE 705,6-Dihydro-N,N-dimethyl-4H-thiodiazolo(4,3,2-ij)quinoline-5-amine2,2-dioxide (Compound 46)

This compound was prepared using the procedure of Example 66, butsubstituting sulfamide for di (2-pyridyl)thiocarbonate and carrying thereaction out at 150° C. in absence of solvent.

EXAMPLE 711,2,6,7-Tetrahydro-6-(dimethylamino)-3H,5H-pyrido(1,2,3-de)quinoxalin-3-one(compound 47)

This compound was prepared using the procedure of Example 66, butsubstituting ethyl bromoacetate for di (2-pyrridyl)thiocarbonate andcarrying the reaction out at the reflux temperature.

EXAMPLE 721,2,6,7-Tetrahydro-6-(dimethylamino)-3H,5H-pyrido(1,2,3-de)quinoxalin-2-one(compound 48)

This compound was prepared using the procedure of Example 66, butsubstituting chloroacetic anhydride for di (2-pyridyl)thiocarbonate andcyclizing the initially formed N⁸-(chloroacetyl)-1,2,3,4-tetrahydro-N³,N³ -dimethyl-3,8-quinolinediamineby heating at 150°0 C. in DMF.

EXAMPLE 736,7-Dihydro-6-(dimethylamino)-3H,5H-pyrido[1,2,3-de)quinoxalin-3-one(compound 49)

This compound was prepared using the procedure of Example 66, butsubstituting butyl glyoxylate for di (2-pyridyl)thiocarbonate andcarrying the reaction out at the reflux temperature.

EXAMPLE 746,7-Dihydro-6-(dimethylamino)-1H,5H-pyrido(1,2,3-di)quinoxalin-2,3-dione(compound 50)

This compound was prepared using the procedure of Example 66, butsubstituting ethyl oxalyl chloride for di (2-pyridyl)thiocarbonate andcarrying the reaction out at the reflux temperature.

EXAMPLE 75 Alternate synthesis of5-(dipropylamino)5,6-dihydro4H-imidazo(4,5,1-ij)quinolin-2(1H)-one(compound 29)

Part A. 4-Methyl-1H-benzimidazolidinone

1,1-Carbonyldiimidazole (30.5 g, 0.19 mol) was added, with cooling, to astirred solution of 3-methyl-1,2-benzenediamine (22.98 g, 0.19 mol) indimethylformamide (200 mL) and the mixture was heated at 100° C. for 1hour. The solvent was removed under reduced pressure until solid beganto appear. Water (200 mL) was slowly added, with stirring, toprecipitate the desired product. The precipitate was filtered off andair-dried overnight to give 26.28 g brown solid, mp >280° C., which wasused without further purification.

Part B. 2-Chloro-4-methyl-1H-benzimidazole

Hydrogen chloride gas was bubbled through a stirred mixture of4-methyl-1H-benzimidazolidone (5 g, 0.034 mol) in phosphorus oxychloride(50 mL) for 1 hour at 120° C. The solvent was removed and the resultingsolid was dissolved in water (50 mL). Ammonium hydroxide (20 mL) wascarefully added until the mixture was basic. The aqueous phase was thenextracted with chloroform, filtered through celite, and evaporated togive 5.2 g, of brown oil. The product was chromatographed on silica gelin chloroform, and was eluted with 1% methanol:chloroform to give 3.96 gof brown oil. Crystallization from ethyl acetate:hexane gave 2.72 g ofbrown crystals, mp 137.5°-139.5° C.

Part C. Methyl 2-chloro-4-methyl-1H-benzimidzole-1-carboxylate

Potassium hydride (0.85 g of 35% in oil, washed with ether to removeoil, 7.4 mmol) was added to a stirred solution of2-chloro-4-methyl-1H-benzimidazole (1.23 g, 7.4 mmol) in THF (25 mL).Methyl chloroformate (0.7 g, 7.4 mmol) was added and the reaction wasstirred 10 minutes. The solvent was removed and the material waspartitioned between ethyl acetate and water. Evaporation of the organiclayer gave 1.68 g of which solid. Crystallization from hexane gave 1.42g of white crystals, mp 90°-91° C. Anal. Calcd. for C₁₀ H₉ ClN₂ O₂ : C,53.47; H, 4.04; Cl, 15.78; N, 12.47. Found: C, 53.63; H, 4.11; Cl,15.81; N, 12.45.

Part D. Methyl 4-(bromomethyl)-2-chloro-1H-benzimidazole-1-carboxylate

A mixture of methyl 4-methyl-2-chloro-1H-benzimidazole-1-carboxylate(17.5 g, 0.078 mol), N-bromosuccinimide (13.9 g, 0.078 mol) and benzoylperoxide (2.0 g) in carbon tetrachloride (175 mL) was stirred at refluxfor 2 hours. The solution was cooled, filtered to remove succinimideby-products, evaporated and crystallized from ethyl acetate:hexane togive 17.1 g ofmethyl-4-(bromomethyl)-2-chloro-1H-benzimidazole-1-carboxylate as a paleyellow solid.

Part E.2-Chloro-5,6-dihydro-N,N-dipropyl-4H-imidazo)4,5,1-ij)quinoline-5-amine(compound 51)

This compound was prepared using the procedure of Example 18, butsubstitutingmethyl-4-(bromomethyl)-2-chloro-1H-benzimidazole-1-carboxylate formethyl-4-(bromomethyl)-1H-benzimidazole-1-carboxylate. The bulk of theproduct was converted to the dihydrochloride salt, mp 165°-170° C.

Part F.5-(Dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinoline-2(1H)-one(compound 29)

2-Chloro-5,6-dihydro-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-aminewas refluxed in acetic acid for 1 hour. The solvent was removed and theresidue was partitioned between ethyl acetate and sodium hydroxidesolution. Evaporation of the ethyl acetate afforded5-(dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinoline-2(1H)-one.

EXAMPLE 761-(1,2,5,6-Tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)pyrrolidine(compound 52)

This compound was prepared by following the procedure of Example 44 partB, but substituting 1-(8-amino-1,2,3,4-tetrahydro-3-quinolyl)pyrrolidinefor t-butyl (8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 771-(1,2,5,6-Tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)piperidine(compound 53)

This compound was prepared by following the procedure of Example 44 partB, but substituting 1-(8-amino-1,2,3,4-tetrahydro-3-quinolyl)piperidinefor t-butyl (8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 784-(1,2,5,6-Tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)morpholine(compound 54)

This compound was prepared by following the procedure of Example 44 partB, but substituting 1-(8-amino-1,2,3,4-tetrahydro-3-quinolyl)morpholinefor t-butyl (8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 791-(2,2,5,6-Tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl)imidazole(compound 55)

This compound was prepared by following the procedure of Example 44 partB, but substituting 1-(8-amino-1,2,3,4-tetrahydro-3-quinolyl)imidazolefor t-butyl (8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 801-(1,2,5,6-Tetrahydro-2-oxo-4H-imidazo(4,5,1-ij)quinolin-5-yl-4-methylpiperazine(compound 56)

This compound was prepared by following the procedure of Example 44 partB, but substituting1-(8-amino-1,2,3,4-tetrahydro-3-quinolyl)-4-methylpiperazine for t-butyl(8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 815-((Phenylmethyl)methylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinoline-2(1H)-one(compound 57)

This compound was prepared by following the procedure of Example 44 partB, but substituting 1,2,3,4-tetrahydro-N³ -methyl-N³-(phenylmethyl)quinoline-3,8-diamine for t-butyl(8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate. The bulk of theproduct was converted to the hydrochloride salt, mp 145°-149° C. frommethanol/ether.

EXAMPLE 825-(Dipropylamino)-7-chloro-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one(compound 58)

This compound was prepared by following the procedure of Example 44 partB, but substituting 5-chloro-1,2,3,4-tetrahydro-N³,N³-dipropyl-3,8-quinolinediamine for t-butyl(8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 835-(Dipropylamino)-5,6-dihydro-7-methyl-4H-imidazo(4,5,1-ij)quinoline-2(1H)-one(compound 59)

This compound was prepared by following the procedure of Example 44 partB, but substituting 1,2,3,4-tetrahydro-5-methoxy-N³,N³-dipropyl-3,8-quinolinediamine for t-butyl(8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 845-(Dipropylamino)-5,6-dihydro-8-methoxy-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one(compound 60)

This compound was prepared by following the procedure of Example 44 partB, but substituting 1,2,3,4-tetrahydro-6-methoxy-N³,N³-dipropyl-3,8-quinolinediamine for t-butyl(8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 855-(Dipropylamino)-5,6-dihydro-9-methoxy-4H-imidazo(4,5,1-ij)quinoline-2(1H)-one(compound 61)

This compound was prepared by following the procedure of Example 44 partB, but substituting 1,2,3,4-tetrahydro-7-methoxy-N³,N³-dipropyl-3,8-quinolinediamine for t-butyl(8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 865-(Dimethylamino)-5,6-dihydro-8-methoxy-4H-imidazo(4,5,1-ij)quinoline-2(1H)-one(compound 62)

This compound was prepared by following the procedure of Example 44 partB, but substituting, 1,2,3,4-tetrahydro-6methoxy-N³,N³ -dimethyl-3,8-quinolinediamine for t-butyl(8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 875-(Dimethylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-8-ol(compound 63)

This compound was prepared by following the procedure of Example 32, butsubstituting5-(dimethylamino)-5,6-dihydro-8-methoxy-4H-imidazo(4,5,1-ij)quinoline-2(1H)-onefor5,6-dihydro-7-methoxy-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine.

EXAMPLE 885,6-Dihydro-6-methyl-N,N-dimethyl-4H-imidazo(4,5,1-ij)quinoline-5-amine(compound 64)

Part A. 4-Ethyl-1H-benzimidazole

This compound was prepared following the procedure of Example 16, butsubstituting 4-bromo-2-ethyl-6-nitroaniline for 2-methyl-6-nitroaniline.

Part B. t-Butyl 4-(1-bromoethyl)-1H-benzimidazole-1-carboxylate

This compound was prepared following the procedure of Example 17, butsubstituting 4-ethyl-1H-benzimidazole for 4-methyl-1H-benzimidazole.

Part C.5,6-Dihydro-6-methyl-N,N-dimethyl-4H-imidazo(4,5,1-ij)quinolin-5-amine

This compound, a mixture of diasteromers, was prepared following theprocedure of Example 19, but substituting t-butyl4-(1-bromomethyl)-1H-benzimidazole-1-carboxylate for t-butyl4-(1-bromomethyl)-1H-benzimidazole-1-carboxylate.

EXAMPLE 895,6-Dihydro-6-methyl-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine(compound 65)

This compound, a mixture of diasteromers, was prepared following theprocedure of Example 88 part C, but substituting methyl benzyl(dipropylamino)malonate for methyl benzyl (dimethylamino) malonate. Theproduct was crystallized from hexane; mp 78°-84° C. Anal. Calcd. for C₁₇H₂₃ N₃ O: C, 75.23; H, 9.28; H, 15.48. Found: C, 75.00; H, 9.47; N,15.54.

EXAMPLE 905-(Dimethylamino)-5,6-dihydro-6-methyl-4H-imidazo(4,5,1-ij)quinolin-2(1H)-onehydrochloride (compound 66)

This compound, a mixture of diastereomers, was prepared following theprocedure of Example 44 part B, but substituting1,2,3,4-tetrahydro-4-methyl-N³,N³ -dimethyl-3,8-quinolinediamine fort-butyl-(8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 915-(Dipropylamino)-5,6-dihydro-6-methyl-4H-imidazo(4,5,1-ij)quinolin-2(1H)-onehydrochloride (compound 67)

This compound, a mixture of diastereomers, was prepared following theprocedure of Example 44 part B, but substituting1,2,3,4-tetrahydro-4-methyl-N³,N³ -dipropyl-3,8-quinolinediamine fort-butyl (8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 92 5,6-Dihydro-4-methyl-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine (compound 68)

Part A. β-(dipropylamino)-1H-benzimidazole-4-propanal

Oxalyl chloride (1.2 mL, 0.014 mol) was added with stirring to methylenechloride (20 mL) at -78° C. Ten minutes after addition was complete,DMSO (2 mL) was added and stirring was continued for an additional 10minutes. β-Dipropylamino)-1H-benzimidazole-4-propanol (2.1 g, 7.5 mmol)in methylene chloride was added and, after 30 minutes, the solution wasallowed to warm to room temperature. Water was added, the methylenechloride was separated and evaporated, and the residue waschromatographed on silica gel to giveβ-(dipropylamino)-1H-benzimidazole-4-propanal as an oil.

Part B. β-(dipropylamino)-α-methyl-1H-benzimidazole-4-propanol

Methyl magnesium bromide (3.3 mL) of 3.0M in ether, 6 mmol) was added toa stirred solution of β-(dipropylamino)-1H-benzimidazole-4-propanal(1.45 g, 5 mmol) in THF (25 mL). The solution was stirred for 1 hour,evaporated, and partitioned between ethyl acetate and water. The ethylacetate was evaporated and the residue was chromatographed on silica gelto give β-(dipropylamino)-α-methyl-1H-benzimidazole-4-propanol as anoil.

Part C.5,6-Dihydro-4-methyl-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine

This compound, a mixture of diastereomers, was prepared following theprocedure of Example 18 part D, but substitutingβ-(dipropylamino)-α-methyl-1H-benzimidzole-4-propanol forβ-(dipropylamino)1H-benzimidzole-4-propanol.

EXAMPLE 935,6-Dihydro-4-methyl-N,N-dimethyl-4H-imidazo(4,5,1-ij)quinolin-5-amine(compound 69)

This compound, a mixture of diastereomers, was prepared following theprocedure of Example 18 part D, but substituting β-(dimethylamino)-α-methyl-1H-benzimidazole-4-propanol forβ-(dipropylamino)-1H-benzimidazole-4-propanol.

EXAMPLE 945-(Dipropylamino)-5,6-dihydro-4-methyl-4H-imidazo-(4,5,1-ij)quinolin-2(1H)-onehydrochloride (compound 70)

This compound, a mixture of diastereomers, was prepared following theprocedure of Example 44 part B, but substituting1,2,3,4-tetrahydro--2-methyl-N³, N³ -dipropyl-3,8-quinolinediamine fort-butyl (8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 955-(Dimethylamino)-5,6,-dihydro-4-methyl-4H-imidazo-(4,5,1-ij)quinolin-2(1H)-onehydrochloride (compound 71)

This compound, a mixture of diastereomers, was prepared following theprocedure of Example 44 part B, but substituting1,2,3,4-tetrahydro-2-methyl-N³, N³ -dimethyl-3,8-quinolinediamine fort-butyl (8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate.

EXAMPLE 965-(Dipropylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-one(compound 72)

Part A. N-Acetyl-N-(2-methoxy-6-methylphenyl)acetamide (compound XLV)

Palladium charcoal (1.0 g of 10%) was added to a solution of3-methyl-2-nitroanisole (16.8 g, 0.1 mol) in ethanol (150 mL) and thesolution was hydrogenated (50 lb initial hydrogen pressure) untilhydrogen uptake ceased (2 hours). The solution was filtered andevaporated to give 13.8 g of 2-methoxy-6-methylbenzenamine (compoundXLIV) as an oil. The product was dissolved in acetic anhydride (100 mL)and the resulting solution was refluxed for 1 hour. Part of the solvent(50 mL) was slowly removed over a 1-hour period, after which time thesolution was cooled and the remainder of the solvent was removed underreduced pressure. The residual oil was crystallized from ethylacetate:hexane (200 mL of 1:2) to give 20.5 g ofN-acetyl-N-(2-methoxy-6-methylphenyl)-acetamide, mp 116°-119° C. AnalCalcd for C₁₂ H₁₅ NO₃ : C, 65.14; H, 6.83; N, 6.33. Found: C, 65.44; H,7.04; N, 6.39.

Part B. N-Acetyl-N-(2-(bromomethyl)-6-methoxyphenyl)acetamide (compoundXLVI)

A mixture of N-acetyl-N-(2-methoxy-6-methylphenyl)acetamide (25.0 g,0.11 mol), N-bromosuccinimide (20.1 g, 0.11 mol), and benzoyl peroxide(4.5 g, 0.019 mol) in carbon tetrachloride (300 mL) was stirred underreflux for 3 hours. The solution was cooled, filtered, and evaporated,and the residual solid was crystallized from ethyl acetate:hexane togive 21.0 g of N-acetyl-N-(2-(bromomethyl)-6-methoxyphenyl)acetamide,95% pure by GC analysis.

Part C. Diethyl(dipropylamino){(2-diacetylamino)-3-methoxyphenyl)-methyl}propanedioate(compound XLVII)

Potassium hydride (13.4 g of 35%, 117 mmol) was added to a stirredsolution of diethyl dipropylaminomalonate (34.6 g, 133 mmol) in the THF(200 mL). N-Acetyl-N-(2-(bromomethyl)-6-methoxyhenyl)acetamide (10.0 g,33 mmol) was added and the solution was heated under reflux for 1 hour.The solution was evaporated and the residual oil was partitioned betweenethyl acetate and water. After evaporation of the ethyl acetate, theresidue was chromatographed on silica gel using ethyl acetate:hexane(1:10 as the eluant to give 9.2 g of diethyl(dipropylamino){(2-diacetylamino)-3-methoxyphenyl)methyl}propanedioate.Crystallization from ethyl acetate:hexane gave 8.4 g of product, mp72°-75° C. Anal Calcd for C₂₅ H₃₈ N₂ O₇ : C, 62.74; H, 8.00; N, 5.85.Found: C, 62.59; H, 8.00; N, 5.87.

Part D. 3-(Dipropylamino)-3,4-dihydro-8-methoxy-2(1H)quinolinone(compound XLVIII)

Diethyl(dipropylamino){2-diacetylamino)-3-methoxyphenyl)methyl}propanedioate(6.34 g) was dissolved in sodium ethoxide in ethanol (150 mL of 1.4M).After 20 min, the solution was heated under reflux for 15 hours; waterwas added to the reaction after 1 hour (1 mL), 3 hours (2 mL), 4 hours(5 mL) and 5 hours (15 mL). The solution was filtered to removeprecipitated inorganic material and the solvents were removed underreduced pressure, and the residue was partitioned between ethyl acetateand water. The oil obtained after evaporation of the ethyl acetate waschromatographed on silica gel to give 3.3 g of3-(dipropylamino)-3,4-dihydro-8-methoxy-2(1H)quinolinone. The productwas crystallized from pentane to give 2.0 g of product, mp 50°-54° C.Anal Calcd for C₁₆ H₂₄ N₂ O₂ : C, 69.53; H, 8.75; N, 10.14. Found: C,69.56; H, 8.98; N, 10.24.

Part E. 1,2,3,4-Tetrahydro-8-methoxy-N,N-dipropyl-3-quinolinamine(compound XLIX)

Lithium aluminum hydride (1.08 g, 27.7 mmol) was added to a stirredsolution of 3-(dipropylamino)-3,4-dihydro-8-methoxy-2(1H)quinolinone(1.05 g, 3.8 mmol) in THF (50 mL) and the solution was heated to 50° C.for 1 hour. After cooling, ethyl acetate followed by methanol were addedto destroy excess hydride, and the solvent was evaporated. The residuewas partitioned between ethyl acetate and water. Evaporation of theethyl acetate gave 0.98 g of1,2,3,4-tetrahydro-8-methoxy-N,N-dipropyl-3-quinolinamine as an oil.

Part F. 1,2,3,4-Tetrahydro-8-hydroxy-N,N-dipropyl-3-quinolinamine(compound L)

A solution of 1,2,3,4-tetrahydro-8-methoxy-N,N-dipropyl-3-quinolinamine(0.98 g) in hydrobromic acid (20 mL of 48%) was heated at 155° C. for 6hours. The solution was cooled, evaporated, and partitioned betweenethyl acetate and saturated sodium bicarbonate solution. The aqueousphase was re-extracted with ethyl acetate and the combined organicphases were evaporated to give 0.88 g of1,2,3,4-tetrahydro-8-hydroxy-N,N-dipropyl-3-quinolinamine as an oil.

Part G.5-(Dipropylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-one(compound 72)

Carbonyldiimidazole (0.46 g, 2.8 mmol) was added to a stirred solutionof 1,2,3,4-tetrahydro-8-hydroxy-N,N-dipropyl-3-quinolinamine (0.59 g,2.4 mmol) in THF (10 mL). After 5 minutes, the solvent was removed andthe residue was dissolved in ethyl acetate and chromatographed on silicagel using 5% ethyl acetate in hexane as the initial eluant to give 0.57g of 5-(dipropylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-oneas an oil.

The bulk of the product was converted to the p-toluenesulfonate salt, mp192°-194° C. from methanol:ether. Anal Calcd for C₁₆ H₂₂ N₂ O₂ -C₇ H₈ O₃S: C, 61.86; H, 6.77; N, 6.28; S, 7.18. Found: C, 61.90; H, 6.97; N,6.28; S, 7.18.

EXAMPLE 975-(Propylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-one(compound 73)

Part A.5-(N-(phenylmethyl)propylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-one

This compound was obtained by following the procedure of Example 96, butsubstituting diethyl (N-(phenylmethyl)propylamino)malonate for diethyl(dipropylamino)malonate.

Part B.5-(Propylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-one

This compound was obtained by following the procedure of Example 66 partA, but substituting5-(N-(phenylmethyl)propylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-onefor 6-bromo-1,2,3,4-tetrahydro-8-nitro-N,N-dimethyl-3-quinolinamine.

EXAMPLE 985-(Dimethylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-one(compound 74)

This compound was prepared following the procedure of Example 96, butsubstituting diethyl (dimethylamino)malonate for diethyl(dipropylamino)malonate.

EXAMPLE 995-(N-methyl-1-(phenyl)ethylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-one(compound 75)

This compound was prepared following the procedure of Example 96, butsubstituting diethyl (N-methyl-2-(phenyl)ethylamino)malonte for diethyl(dipropylamino)malonate.

EXAMPLE 1001-(5,6-Dihydro-2-oxo-2H,4H-oxazolo(5,4,3-ij)quinolin-5-yl)pyrrolidine(compound 76)

This compound was prepared by following the procedure of Example 96, butsubstituting (1-pyrrolidinyl)propanedioic acid methyl benzyl diester(compound VIk) for diethyl dipropylaminomalonate.

EXAMPLE 1011-(5,6-Dihydro-2-oxo-2H,4H-oxazolo(5,4,3-ij)quinolin-5-yl)piperidine(compound 77)

This compound was prepared by following the procedure of Example 96, butsubstituting (1-piperidinyl)propanedioic acid methyl benzyl diester(compound VIm) for diethyl dipropylaminomalonate.

EXAMPLE 1024-(5,6-Dihydro-2-oxo-2H,4H-oxazolo(5,4,3-ij)quinolin-5-yl)morpholine(compound 78)

This compound was prepared by following the procedure of Example 96, butsubstituting (4-morpholinyl)propanedioic acid methyl benzyl diester(compound VIn) for diethyl dipropylaminomalonate.

EXAMPLE 1031-(5,6-Dihydro-2-oxo-2H,4H-oxazolo(5,4,3-ij)quinolin-5-yl)imidazole(compound 79)

This compound was prepared by following the procedure of Example 96, butsubstituting (1-imidazolyl)propanedioic acid methyl benzyl diester(compound VIp) for diethyl dipropylaminomalonate.

EXAMPLE 1045-(Dipropylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-thione(compound 80)

This compound was prepared by following the procedure of Example 56 partB, but substituting1,2,3,4-tetrahydro-8-hydroxy-N,N-dipropyl-3-quinolinamine for1,2,3,4-tetrahydro-N³,N³ -dipropyl-3,8-quinolinamine.

EXAMPLE 1055-(Dimethylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-thione(compound 81)

This compound was prepared by following the procedure of Example 56 partB, but substituting1,2,3,4-tetrahydro-8-hydroxy-N,N-dimethyl-3-quinolinamine for1,2,3,4-tetrahydro-N³,N³ -dipropyl-3,8-quinolinediamine.

EXAMPLE 1066-(Dipropylamino)-6,7-dihydro-5H-pyrido(1,2,3-de)-1,4-benzoxazin-3(H)-one(compound 82)

This compound was prepared by following the procedure of Example 56 partB, but substituting ethyl bromoacetate for di (2-pyridyl)thiocarbonateand the sodium salt of1,2,3,4-tetrahydro-8-hydroxy-N,N-dipropyl-3-quinolinamine for1,2,3,4-tetrahydro-N³, N³ -dipropyl-3,8-quinolinediamine. The bulk ofthe product was converted to the maleate salt, mp 124°-127° C.

EXAMPLE 1076-(Dimethylamino)-6,7-dihydro-5H-pyrido(1,2,3-de)-1.4-benzoxazin-3(2H)-one(compound 83)

This compound was prepared by following the procedure of Example 56 partB, but substituting ethyl bromoacetate for di (2-pyridyl)thiocarbonateand the sodium salt of1,2,3,4-tetrahydro-8-hydroxy-N,N-dimethyl-3-quinolinamine for1,2,3,4-tetrahydro-N³,N³ -dipropyl-3,8-quinolinediamine.

EXAMPLE 1081,2,6,7-Tetrahydro-6-(dipropylamino)-2-methyl-3H,5H-pyrido(1,2,3-de)quinoxalin-3-one(compound 84)

This compound was prepared using the procedure of Example 56, butsubstituting ethyl α-bromopropionate for di (2-pyridyl)thiocarbonate andcarrying the reaction out at the reflux temperature. The crude productwas chromatographed to give, as the major product and first compoundeluted from the column,1,2,6,7-tetrahydro-6-(dipropylamino)-2-methyl-3H,5H-pyrido(1,2,3-de)quinoxalin-3-one.

EXAMPLE 1091,2,6,7-Tetrahydro-6-(dipropylamino)-3-methyl-3H,5H-pyrido(1,2,3-de)quinoxalin-2-one(compound 85)

This compound was prepared using the procedure of Example 56, butsubstituting chloropropionyl chloride for di (2-pyridyl)thiocarbonate.The initially formed N⁸ -(α-chloropropionyl)-1,2,3,4-tetrahydro-N³,N³-dipropyl-3,8-quinolinediamine was heated at 150° C. in DMF to effectcyclization to1,2,6,7-tetrahydro-6-(dipropylamino)-3-methyl-3H,5H-pyrido(1,2,3-de)quinoxalin-2-one.

EXAMPLE 1105,6-Dihydro-N,N-dipropyl-4H-pyrrolo(3,2,1-ij)quinolin-5-amine (compound86)

This compound was prepared by following the procedure of Example 18, butsubstituting methyl 7-(bromomethyl)-1H-indole-1-carboxylate for t-butyl4-(bromomethyl)-1H-benzimidazole-1-carboxylate.

EXAMPLE 111 5,6-Dihydro-N,N-dimethyl-4H-pyrrolo(3,2,1ij)quinolin-5-amine(compound 87)

This compound was prepared by following the procedure of Example 18, butsubstituting methyl 7-(bromomethyl)-1H-indole-1-carboxylate for t-butyl4-(bromomethyl)-1H-benzimidazole-1-carboxylate and diethyl(dimethylamino)malonte for diethyl (dipropylamino)malonate. The bulk ofthe product was converted to the maleate salt, mp 114°-115° C. fromTHF/ether.

EXAMPLE 1125,6-Dihydro-N,N-dipropyl-4H-pyrazolo(4,3,2-i)quinolin-5-amine (compound88)

This compound was prepared by following the procedure of Example 18, butsubstituting methyl 7-(bromomethyl)-1H-indazole-1-carboxylate fort-butyl 4-(bromomethyl)-1H-benzimidazole-1-carboxylate.

EXAMPLE 1135,6-Dihydro-N,N-dimethyl-4H-pyrazolo(4,3,2-ij)quinolin-5-amine (compound89)

This compound was prepared by following the procedure of Example 18, butsubstituting methyl 7-(bromomethyl)-1H-indazole-1-carboxylate fort-butyl 4-(bromomethyl)-1H-benzimidazole-1-carboxylate and diethyl(dimethylamino)malonate for diethyl (dipropylamino)malonate.

EXAMPLE 1145,6-Dihydro-N,N-dipropyl-4H-triazolo(4,5,1-ij)quinolin-5-amine (compound90)

This compound was prepared by following the procedure of Example 18, butsubstituting methyl 4-(bromomethyl)-1H-benzotriazole-1-carboxylate fort-butyl 4-(bromomethyl)-1H-benzimidazole-1-carboxylate.

EXAMPLE 1155,6-Dihydro-N,N-dimethyl-4H-triazolo(4,5,1-ij)quinolin-5-amine (compound91)

This compound was prepared by following the procedure of Example 18, butsubstituting methyl 4-(bromomethyl)-1H-benzotriazole-1-carboxylate fort-butyl 4-(bromomethyl)-1H-benzimidazole-1-carboxylate and diethyl(dimethylamino)-malonate for diethyl (dipropylamino)malonate.

EXAMPLE 1161,2,5,6-Tetrahydro-N,N-dipropyl-4H-pyrrolo(3,2,1-ij)quinolin-5-amine(compound 92)

This compound was prepared by following the procedure of Example 18, butsubstituting t-butyl 2,3-dihydro-7-(bromomethyl)-1H-indole-1-carboxylatefor t-butyl 4-(bromomethyl)-1H-benzimidazole-1-carboxylate. The bulk ofthe product was converted to the maleate salt, mp 139°-140° C. fromTHF/ether.

EXAMPLE 1171,2,5,6-Tetrahydro-N,N-dimethyl-4H-pyrrolo(3,2,1-ij)quinolin-5-amine(compound 93)

This compound was prepared by following the procedure of Example 18, butsubstituting t-butyl 2,3-dihydro-7-(bromomethyl)-1H-indole-1-carboxylatefor t-butyl 4-(bromomethyl)-1H-benzimidazole-1-carboxylate and diethyl(dimethylamino)malonate for diethyl (dipropylamino)malonate.

EXAMPLE 1185-(Propylamino)-5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-2,3H)-dione(compound 94)

Part A.N-Propyl-N-(6-bromo-1,2,3,4-tetrahydro-8-nitroquinolin-3-yl)formamide.

This product was prepared by following the procedure of Example 35, butsubstituting 6-bromo-1,2,3,4-tetrahydro-8-nitro-N-propyl-3-quinolinaminefor 3-aminoquinoline.

Part B. N-propyl-N-(8-amino-1,2,3,4-tetrahydro-3-quinolyl)formamide

This product was prepared by following the procedure of Example 56 partA, but substitutingN-propyl-N-(6-bromo-1,2,3,4-tetrahydro-8-nitro-3-quinolyl for6-bromo-1,2,3,4-tetrahydro-8-nitro-N,N-dipropyl-3-quinolinamine.

Part C.N-propyl-N-(5,6-dihydro-2,3-dioxo-4H-pyrrolo(3,2,1-ij)quinolin-5-yl)formamide

Oxalyl chloride (1.26 g, 0.01 mol) was added to a stirred solution ofN-propyl-N-(6-bromo-1,2,3,4-tetrahydro-8-nitroquinolin-3-yl)formamide(3.14 g, 0.01 mol) in ether (100 mL). After 30 minutes, the ether wasremoved and the residue was heated at 100° C. for 4 hours to effectcyclization. The crude product was partitioned between ethyl acetate andwater, the ethyl acetate phase was evaporated, and the residual productwas chromatographed on silica gel to giveN-propyl-N-(5,6-dihydro-2,3-dioxo-4H-pyrrolo(3,2,1-ij)quinolin-5-yl)formamide.

Part D.5-(Propylamino)-5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-2,3-dione(compound 94)

N-Propyl-N-(5,6-dihydro-2,3-dioxo-4H-pyrrolo(3,2,1-ij)quinolin-5-yl)formamidewas refluxed for 1 hour with ethanolic hydrogen chloride to give thehydrochloride salt of5-(propylamino)-5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-2,3-dione.

EXAMPLE 1195-(Dipropylamino)-5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1,3-dione(compound 95)

This product was prepared by following the procedure of Example 54, butsubstituting5-(propylamino)-5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-2,3H)-dionehydrochloride for 6-bromo-1,2,3,4-tetrahydro-8-nitro-3-quinolinaminedihydrochloride.

EXAMPLE 1205-(Propylamino)-5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-2(1H)-one(compound 96)

This product was prepared by following the procedure of Example 36, butsubstituting5-(propylamino)-5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-2,3-dione forN-(3-quinolyl)formamide.

EXAMPLE 1215-(Dipropylamino)-5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-2(1H)-one(compound 97)

This product was prepared by following the procedure of Example 36, butsubstituting5-(dipropylamino)-5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-2,3-dione forN-(3-quinolyl)formamide. The product was crystallized from hexane, mp86°-88° C.

EXAMPLE 1226-(Dipropylamino)-2,3,6,7-tetrahydro-5H-pyrido(3,2,1-ij)quinazolin-3one(compound 98)

Part A. Methyl 3-methyl-2-nitrobenzoate

3-Methyl 2-nitrobenzoic acid (15.0 g) was stirred overnight withmethanolic hydrogen chloride (150 mL of 2.2N). The reaction was thenrefluxed for 3 hours, cooled and filtered to give 9.0 g of methyl3-methyl-2-nitrobenzoate, mp 72°-75° C. The mother liquors of thefiltration contained a mixture of the starting acid and ester product.

Part B. Methyl 3-(bromomethyl)-2-nitrobenzoate

This product was prepared by following the procedure of Example 6, butsubstituting methyl 3-methyl-2-nitrobenzoate for 8-methylquinoline. Theproduct was purified by chromatography on silica gel and wascrystallized from ethyl acetate:hexane; mp 91°-95° C.

Part C. (Dipropylamino)(3-carbomethoxy-2-nitrophenyl)methyl)propanedioicacid methyl benzyl diester

This product was prepared by following the procedure of Example 19 partA, but substituting methyl 3-(bromomethyl)-2-nitrobenzoate for t-butyl4-(bromomethyl)-1H-benzimidazole-1-carboxylate and(dipropylamino)propanedioic acid methyl benzyl diester for diethyl(dipropylamino)malonate.

Part D. Methyl3-(dipropylamino)-1,2,3,4-tetrahydro-2-oxo-8-quinolinecarboxylate

A mixture of(dipropylamino)(3-carbomethoxy-2-nitrophenyl)methyl)propanedioic acidmethyl benzyl diester (5.0 g), 10% palladium charcoal (0.5 g) inmethanol (150 mL) was hydrogenated until hydrogen uptake ceased. Thesolution was filtered and the solvent removed to give 3.0 g of methylα-(dipropylamino)-(2-amino-3-carbomethoxyphenyl)propanoate as an oil.This was refluxed in DMF for 18 hours to effect cyclization. The solventwas removed and the residual oil was chromatographed on silica gel togive 2.4 g of methyl3-(dipropylamino)-1,2,3,4-tetrahydro-2-oxo-8-quinolinecarboxylate.

Part E. 3-(Dipropylamino)-1,2,3,4-tetrahydro-2-oxo-8-quinolinecarboxylicacid

A mixture of methyl3-(dipropylamino)-1,2,3,4-tetrahydro-2-oxo-8-quinolinecarboxylate (1.0g), methanol (15 mL) and 4.0N sodium hydroxide solution (3.3 mL) wasstirred at room temperature for 30 minutes. The methanol was removed andthe residue was reconstituted in water (5 mL) and neutralized byaddition of 4.0N hydrochloric acid (3.3 mL). The precipitate wasfiltered off, washed with water and air dried to give 0.67 g of3-(dipropylamino)-1,2,3,4-tetrahydro-2-oxo-8-quinolinecarboxylic acid,mp 214°-217° C. Anal Calcd for C₁₆ H₂₂ N₂ O₃ : C, 66.18; H, 7.64; N,9.65. Found: C, 65.99; H, 7.67; N, 9.62.

Part F.3-(Dipropylamino)-1,2,3,4-tetrahydro-2-oxo-8-quinolinecarboxamide

A mixture of3-(dipropylamino)-1,2,3,4-tetrahydro-2-oxo-8-quinolinecarboxylic acid(1.0 g), 1-hydroxybenzotriazole (1.65 g, 11 mmol) anddicyclohexylcarbodiimide (3.09 g, 15 mmol) in dimethylformamide (25 mL)was stirred at room temperature for 15 minutes. Ammonia was then bubbledinto the solution, and, after 15 minutes the solution was filtered,evaporated and partitioned between ethyl acetate and sodium hydroxidesolution. The ethyl acetate was evaporated and the residual solid waspurified by chromatography on silica gel using ethyl acetate as theeluant to give 0.98 g of product. This was crystallized from methanol togive 0.78 g of3-(dipropylamino)-1,2,3,4-tetrahydro-2-oxo-8-quinolinecarboxamide, mp214°-217° C. Anal Calcd for C₁₆ H₂₃ N₃ O₂ : C, 66.41; H, 8.01; N, 14.52.Found: C, 66.46; H, 8.30; N, 14.69.

Part G. 1,2,3,4-Tetrahydro-8-(aminomethyl)-N,N-dipropyl-3-quinolinamine

Lithium aluminum hydride (1.5 g) was added to a stirred solution of3-(dipropylamino)-1,2,3,4-tetrahydro-2-oxo-8-quinolinecarboxamide (0.75g) in THF (125 mL) and the solution was refluxed for 2 days. Thesolution was cooled and excess hydride was destroyed by addition ofmethanol (20 mL) and the solvents were removed under reduced pressure.The residue was partitioned between ethyl acetate (400 mL) and water (15mL). The ethyl acetate was decanted from the inorganic solids and thesolvent removed under reduced pressure. The residual oil was dissolvedin chloroform and chromatographed on silica gel. Elution of the columnwith 5% methanol:chloroform gave 0.40 g of1,2,3,4-tetrahydro-8-(aminomethyl)-N,N-dipropyl-3-quinolinamine.

Part H.6-(Dipropylamino)-2,3,6,7-tetrahydro-5H-pyrido(3,2,1-ij)quinazolin-3-one(compound 98)

This compound was prepared by following the procedure of Example 96 partG, but substituting1,2,3,4-tetrahydro-8-(aminomethyl)-N,N-dipropyl-3-quinolinamine for1,2,3,4-tetrahydro-8-hydroxy-N,N-dipropyl-3-quinolinamine. The productwas crystallized from hexane; mp 116°-119° C.

EXAMPLE 1236-(Dimethylamino)-2,3,6,7-tetrahydro-5H-pyrido(3,2,1-ij)quinazolin-3-one(compound 99)

This compound was prepared by following the procedure of Example 122,but substituting (dimethylamino)propanedioic acid methyl benzyl diesterfor (dipropylamino)propanedioic acid methyl benzyl diester in part C ofthe reaction sequence.

EXAMPLE 1246l-(Dipropylamino)-6,7-dihydro-1H,5H-pyrido(1,2,3-de)-2,4-benzoxazine-3-one(compound 100)

Part A.1,2,3,4-Tetrahydro-8-(hydroxymethyl)-N,N-dipropyl-3-quinolinamide

This compound was obtained by following the procedure of Example 122part G, but substituting methyl3-(dipropylamino)-1,2,3,4-tetrahydro-2-oxo-8-quinolinecarboxylate for3-(dipropylamino)-1,2,3,4-tetrahydro-2-oxo-8-quinolineoxamide.

Part B.6-(Dipropylamino)-6,7-dihydro-1H,5H-pyrido(1,2,3-de)-2,4-benzoxanine-3-one(compound 100)

This compound was prepared by following the procedure of Example 44 partB, but substituting1,2,3,4-tetrahydro-8-(hydroxymethyl)-N,N-dipropyl-3-quinolinamine fort-butyl(8-amino-1,2,3,4-tetrahydro-3-quinolyl)carbamate. The bulk of theproduct was converted to the hydrochloride salt, mp 192°-195° C.

EXAMPLE 125 6-(Dimethylamino)-6,7-dihydro-1H,5H-pyrido(3,2,1-ef)-2,4-benzoxanine-3-one (compound 101)

This compound was obtained by following the procedure of Example 124,but substituting methyl3-(dimethylamino)-1,2,3,4-tetrahydro-2-oxo-8-quinolinecarboxylate formethyl3-(dipropylamino)-1,2,3,4-tetrahydro-2-oxo-8-quinolinecarboxylate.

EXAMPLE 1266-(Dipropylamino)-6,7-dihydro-3H,5H-benzo(ij)quinolizin-3-one (compound102)

Part A. 5-(Dipropylamino)-1,2,3,4-tetrahydro-8-quinolinecarboxaldehyde

This compound was obtained by following the procedure of Example 92 partA, but substituting1,2,3,4-tetrahydro-8-(hydroxymethyl)-N,N-dipropyl-3-quinolinamine forβ-(dipropylamino)-1H-benzimidazole-4-propanol.

Part B. 6-(Dipropylamino)-6,7-dihydro-3H,5H-benzo(ij)quinolizin-3-one(compound 102)

A mixture of5-(dipropylamino)-1,2,3,4-tetrahydro-8-quinolinecarboxaldehyde (2.60 g,0.01 mol), diethyl malonate (1.76 g, 0.011 mol), piperidine (0.3 g) andacetic acid (0.1 mL) in ethanol (20 mL) was refluxed for 6 hours. Thesolvents were removed and the residue was reconstituted in DMF andrefluxed for 3 hours. The DMF was removed and the residue waschromatographed to give6-(dipropylamino)-6,7-dihydro-3-oxo-3H,5H-benzo(ij)quinolizin-2-carboxylate.This was dissolved in ethanol (50 mL) and treated with sodium hydroxidesolution (10 mL of 4N) for 1 hour. The solution was neutralized withhydrochloric acid to give6-(dipropylamino)-6,7-dihydro-3H,5H-benzo(ij)quinolizin-3-one. Theproduct was crystallized from hexane, mp 82°-84° C.

EXAMPLE 1276-(Dimethylamino)-6,7-dihydro-3H,5H-benzo(ij)quinolizin-3-one (compound103)

This compound was obtained by following the procedure of Example 126,but substituting1,2,3,4-tetrahydro-8-(hydroxymethyl)-N,N-dimethyl-3-quinolinamine for1,2,3,4-tetrahydro-8-(hydroxymethyl)-N,N-dipropyl-3-quinolinamine.

EXAMPLE 1286-(Dipropylamino)-2,3,6,7-tetrahydro-3H,5H-benzo(ij)quinolizin-3-one(compound 104)

This product was prepared by following the procedure of Example 36, butsubstituting6-(dipropylamino)-6,7-dihydro-3H,5H-benzo(ij)quinolizin-3-one forN-(3-quinolyl)formamide. The product was crystallized from pentane, mp44°-45° C.

EXAMPLE 1296-(Dimethylamino)-2,3,6,7-tetrahydro-3H,5H-benzo(ij)quinolizin-3-one(compound 105)

This product was prepared by following the procedure of Example 36, butsubstituting6-(dipropylamino)-6,7-dihydro-3H,5H-benzo(ij)quinolizin-3-one forN-(3-quinolyl)formamide.

EXAMPLE 130 t-Butyl1,2,3,4-Tetrahydro-5-(dipropylamino)quinoline-1-carboxylate

A mixture of 1,2,3,4-tetrahydro-N³,N³ -dipropylquinoline (31.4 g, 0.135mol) and di t-butyl dicarbonate (32.5 g, 0.149 mol) was heated at 100°C. for 1 hour. The product was chromatographed on silica gel using ethylacetate:hexane as the eluent to give 42.6 g of t-butyl1,2,3,4-tetrahydro-5-(dipropylamino)quinoline-1-carboxylate, mp 40°-42°C.

A portion of the product was converted to the hydrochloride salt, mp168° C. (dec) from methanol:ether.

EXAMPLE 131 t-Butyl1,2,3,4-Tetrahydro-8-methyl-5-(dipropylamino)-quinoline-1-carboxylate(LII)

s-Butyl lithium (17.7 mL of 1.3M in hexane (0.045 mol) was added at -78°C. to a stirred solution of t-butyl1,2,3,4-tetrahyfro-5-(dipropylamino)quinoline-1-carboxylate (10 g, 0.030mol) in THF (200 mL). After 15 minutes, methyl iodide (17.1 g, 0.13 mol)was added and the solution was allowed to warm to room temperature. TheTHF was removed under pressure, and the residual oil was partitionedbetween ethyl acetate and water. The ethyl acetate was evaporated andthe residual oil was chromatographed on silica gel to afford 10.65 g oft-butyl1,2,3,4-tetrahydro-8-methyl-5-(dipropylamino)quinoline-1-carboxylate asan oil.

EXAMPLE 1325-(Dipropylamino)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-one(compound 97)

Following the procedure of Example 131, but substituting t-butyl1,2,3,4-tetrahydro-8-methyl-5-(dipropylamino)quinoline-1-carboxylate fort-butyl 1,2,3,4-tetrahydro-5-(dipropylamino)quinoline-1-carboxylate andcarbon dioxide for methyl iodide there was obtained1,2,3,4-tetrahydro-1-(t-butoxycarbonyl)-5-(dipropylamino)quinoline-8-propionicacid. The product was treated with trifluoracetic acid to remove thet-butoxycarbonyl group and effect cyclization to5-(dipropylamino)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-one, mp84°-86° C.

EXAMPLE 133 Lithium aluminum hydride reduction of5-(Dipropylamino)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-one(compound 97).

A mixture of5-(dipropylamino)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-one(0.75 g) and lithium aluminum hydride (0.21 g) was stirred in ether (20mL) for 45 minutes. The reaction was quenched with methanol, evaporatedand partitioned between ethyl acetate and water. Evaporation of theethyl gave an oil which was chromatographed on silica gel using ethylacetate:hexane (1:20) as eluant to give, as the first compound elutedfrom the column 0.27 g of5,6-dihydro-N,N-dipropyl-4H-pyrrolo[3,2,1-ij]quinolin-5-amine (compound87). Continued elution of the column gave 0.34 g of1,2,5,6-tetrahydro-N,N-dipropyl-4H-pyrrolo[3,2,1-ij]quinolin-5-amine(compound 92).

EXAMPLE 1345,6-dihydro-5-(dipropylamino)-4H-pyrrolo[3,2,1-ij]quinolin-2,3-dione(compound 95).

Following the procedure of Example 131, but substituting ethyl oxalatefor methyl iodide, there was obtained1,2,3,4-tetrahydro-1-(t-butoxycarbonyl)-α-oxo-5-(dipropylamino)quinoline-8-propionicacid (LIII). The product was treated with trifluoracetic acid to effectcyclization to5,6-dihydro-5-(dipropylamino)-4H-pyrrolo[3,2,1-ij]quinolin-2,3-dione(compound 95)

EXAMPLE 1356-(Dipropylamino)-6,7-dihydro-3H,5H-benzo[ij]quinolizin-3-one (compound102)

Following the procedure of Example 131, but substituting ethyl formatefor methyl iodide there was obtained t-butyl8-formyl-1,2,3,4-tetrahydro-5-(dipropylamino)quinoline-1-carboxylate(LIV) as an oil. The product (3.6 g) was added to a stirred solution oftrimethyl phosphonoacetate (3.64 g) and sodium hydride (0.96 g) inacetonitrile (75 mL). The solution was evaporated, chromatographed toafford 3.6 g of methyl1,2,3,4-tetrahydro-1-(t-butoxycarbonyl)-α-oxo-5-(dipropylamino)quinoline-8-butenoate(LV) as an oil. The product was treated with trifluoracetic acid toremove the t-butoxycarbonyl protecting group and refluxed in ethanol toeffect cyclization to6-(dipropylamino)-6,7-dihydro-3H,5H-benzo[ij]quinolizin-3-one (compound102).

EXAMPLE 136 Allylation of5-(amino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one.

Following the procedure of Example 54, but substituting allyl bromidefor iodopropane and5-(amino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one for6-bromo-1,2,3,4-tetrahydro-8-nitro-3-quinolinamine dihydrochloride therewere obtained5-(diallylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one, mp150-152 from ethyl acetate and5-(allylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one. Thelatter compound was converted to the hydrochloride salt, mp 260° frommethanol:ether.

EXAMPLE 137 Reaction of5-(amino)-5,6-dihydro-4H-imidazo[4,5,1-ij[quinolin-2(1H)-one withcyclopropylmethyl bromide.

Following the procedure of Example 54, but substitutingcyclopropylmethyl bromide for iodopropane and5-(amino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(quinolin-2(1H)-onefor 6-bromo-1,2,3,4-tetrahydro-8-nitro-3-quinolinamine dihydrochloridethere were obtained5-[bis(cyclopropylmethyl)amino]-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one,mp 152-154 from ethyl acetate:hexane and5-(cyclopropylmethylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one.The latter compound was converted to the hydrochloride salt, mp 309° C.(dec) from methanol:ether. ##STR2##

We claim:
 1. A compound of formulaor a pharmaceutically-acceptable saltthereof, wherein R₁, R₂ and R₃ are independently H, C₁₋₆ alkyl, C₃₋₅alkenyl, C₃₋₅ alkynyl, C₃₋₇ cycloalkyl, or C₄₋₁₀ cycloalkyl- orphenyl-substituted C₁₋₆ alkyl, or NR₁ R₂ is pyrrolidine, piperidine,morpholine, 4-methyl piperazine or imidazole; X isa) hydrogen, b) C₁₋₆alkyl, c) halogen, d) hydroxy, e) C₁₋₆ alkoxy, f) cyano, g) carboxamide,h) carboxyl, or i) (C₁₋₆ alkoxy)carbonyl; A isa) CH, CH₂, CH-halogen,CHCH₃, C═O, C═S, C--SCH₃, C═NH, C--NH₂, C--NHCH₃, C--NHCOOCH₃, orC--NHCN; b) SO₂, or c) N; and D isa) CH, CH₂, CH-halogen or C═O, b) O,c) N, NH or N--CH₃.
 2. The compound of claim 1 wherein D is N or NH. 3.The compound of claim 2 wherein A is CH, CH₂, CHCH₃, C═O, C═S, C--SCH₃,C═NH, C--NH₂, C--NHCH₃, C--NHCOOCH₃, or C--NHCN.
 4. The compound ofclaim 3 wherein A is CH or C═O.
 5. The compound of claim 4 which isa)5-(Dimethylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-onehydrochloride b)5-(Propylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one c)5-(Dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-one d)(--)5-(Dipropylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij)quinolin-2(1H)-onee) 5,6-Dihydro-N,N-dipropyl-4H-imidazo(4,5,1-ij)quinolin-5-amine f)5,6-Dihydro-N-propyl-4H-imidazo(4,5,1-ij)quinoline-5-amine g)5,6-Dihydro-5-(dipropylamino)-4H-imidazo(4,5,1-ij)quinolin-8-ol.
 6. Thecompound of claim 1 wherein D is O and A is CH, CH₂, CHCH₃, C═O, C═S,C--SCH₃, C═NH, C--NH₂, C--NHCH₃, C--NHCOOCH₃, or C--NHCN.
 7. Thecompound of claim 6 wherein A is C═O or C═S.
 8. The compound of claim 7which isa)5-(Dipropylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-one b)5-(Propylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-one c)5-(Dimethylamino)-5,6-dihydro-2H,4H-oxazolo(5,4,3-ij)quinolin-2-one. 9.The compound of claim 1 wherein D is CH, CH₂, or C═O.
 10. The compoundof claim 9 which isa)5,6-Dihydro-N,N-dipropyl-4H-pyrrolo(3,2,1-ij)quinolin-5-amine b)5,6-Dihydro-N,N-dimethyl-4H-pyrrolo(3,2,1-ij)quinolin-5-amine c)5,6-Dihydro-N,N-dipropyl-4H-pyrazolo(4,3,2-ij)quinolin-5-amine d)5,6-Dihydro-N,N-dimethyl-4H-pyrazolo(4,3,2-ij)quinolin-5-amine e)1,2,5,6-Tetrahydro-N,N-dipropyl-4H-pyrrolo(3,2,1-ij)quinolin-5-amine f)1,2,5,6-Tetrahydro-N,N-dimethyl-4H-pyrrolo(3,2,1-ij)quinolin-5-amine g)5-(Propylamino)-5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-2,3-dione h)5-(Dipropylamino)-5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-2,3-dione i)5-(Propylamino)-5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-2(1H)-one j)5-(Dipropylamino)-5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-2(1H)-one 11.A method for treating central nervous system disorders in animal orhuman hosts in need thereof comprising the administration of apharmaceutically effective amount of a compound of claim 1.